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CHAPTER 1. 
BREAST CANCER 
1. INTRODUCTION 
1.1. Epidellliology alld etiology 
Breast cancer is the most common malignant tumour among women in the 
western world, affecting 8-12 % of the female population. In the Netherlands, 
breast cancer occurs yearly in IOOO per IOO,OOO women with an absolute 
incidence of 9,000 new cases per year. 1 The etiology is multifactorial. Age is 
an important risk factor. The incidence climbs after age 30, followed by a slight 
dip at menopause and continues to ri se during postmenopausal years.2.3 
Honnonal influences are weil documented etiological factors: increasing age of 
the mother at birth of her first child increases the risk of breast cancer whereas 
late menarche and early menopause decreases the risk. 4.'.6 An extensive 
collaborative study reanalysing 54 epidemiological studies in 25 countries 
provided evidence for a small increase in the relative risk (1.24) of having 
breast cancer while taking oral contraceptives and in the IO years after quitting, 
with no increased risk IO or more years af ter stopping. 7 
Familial predisposition is considered to be an important risk factor as weil. The 
cumulative risk of a healthy woman developing breast cancer increases from IO 
to 20% if a first degree relative becomes affected. The risk is further increased 
(up to 40%) in families with a mean age at cancer diagnosis of less than 45 
years. 8•9 In these families breast cancer is often found to be of genetic origin, 
and can in the majority of cases now be attributed to mutations of the BRCA-l 
gene (predisposition for breast and ovarian cancer) located on the long arm of 
chromosome 17, and the BRCA-2 gene (predisposition for female and male 
breast cancer), located on the long arm of c1nomosome 13. 10 Until now over 
IOO mutations have been observed in these genes ( 252 different mutations for 
BRCAl, 173 for BRCA2). Tt is anticipated that additional mutant genes 
associated with familial breast cancer will be found. 
Less important risk factors are ionizing radiation, including X-rays, especially 
when exposure has taken place during adolescence or childhood ll •12 and diets 
high in animal fats. 13 Obesity is shown to be a risk factor in the 
postmenopausal age group.14.1' In general, enviroIl1llent and lifestyle 
contribute to the development of breast cancer. Japanese women living in US 
have a higher mortality rate for breast cancer than J apanese women living in 
Japan. 16 Recently, a comprehensive Norwegian study has confirmed the 
findings of others that physical exercise reduces the risk of developing breast 
cancer. 17,18 
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1.2. Precursor lesions. 
A history of atypical hyperplasia, whether lobular or ductal, indicates a 
woman's risk for the development of breast cancel' of 5-10%.'9 Other histolo-
gie categories like adenosis and apocrine changes do not increase a woman's 
risk, meaning that the relative chance of getting breast cancel' is the same as that 
of a reference population. Ductal carcinoma in situ (DCIS) is considered a tme 
precursor les ion and breast cancel' screening programs have led to the detection 
of an increasing number of DeIS: < 5 % in the seventies, up to 15-25 % of the 
total number of detected cancers in the nineties.20·21 DeIS is histologically a 
heterogenous group of lesions, since only one third will progress to invasion in 
the same breast during follow-up of 10-18 years. 20•22 •23 It has therefore 
become increasingly important to classify these lesions in relation to their biolo-
gical behaviour according to strict histological criteria. Lately a new 
classification,24 based primarily on cytonuclear and architectural differentiation 
has been proposed. This classification distinguishes 3 categories of this lesion: 
weil, intermediate and poorly differentiated in situ carcinomas. A highly 
significant correlation was found between the DeIS type and the grade of the 
infiltrating component arising from or located around the DCIS. 25 Moreover 
astrong correlation was seen between the different grades of in situ carcinomas 
and the presence of biological markers, the poorly differentiated being estrogen 
receptor (ER) and progesterone receptor (PR) negative, P53 or Her/2neu 
positive, the weil differentiated showing the reverse phenotype and the 
intermediate a mixed pattern.26•27•28 Lobular carcinoma in situ (LeIS) is rare 
(observed in 0.5 % of symptomatic and in I % of screen-detected cancers20) and 
follows a different course compared to DeIS. About 15-20% of women with 
LeIS will develop breast cancel' in the same breast, a further 10-15 % will 
develop an invasive cancel' in the controlateral breast. 20.29 
1.3. Diagnostic procedures. 
An excisional biopsy was the only available diagnostic method for half a 
century. But since the sixties new diagnostic methods were developed. The 
introduction of fine needie aspiration cytology (FNA) has led to presurgical 
diagnosis of breast tumours. This simpie, patient friendly, cost reducing method 
has an average sensitivity of 87 %, specificity close to 100%, a predictive value 
of positive diagnosis nearly 100%, and a predictive value of negative diagnosis 
between 60_90%.30.31.32.33 The introduction of mammography and uItra-
sound, and the acceptance of FNA as diagnostic tooi, resulted in the triple dia-
gnosis used in the pre-operative work-up of a palpable lesion. Several 
studies"·"·36 have confirmed that this method detects most cancers and has 
reduced the number of frozen sections for the pathology department. 
Breast screening programs and recent advances in mammography, ultrasound 
and magnetic resonance imaging (MRI) , have not only led to an increasing 
number of DeIS but likewise to earlier diagnosis of breast cancel' and therefore 
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to an increasing number of small < 11 nnn, invasive carcinomas (7 % in the 
sixties til! 25%-28% in the nineties21 •37). These tumours are often non-palpable 
and therefore stereotactic or ultrasonographic localisation is needed followed by 
either FNA or, when this is not feasible, needie biopsy or excisional biopsy to 
provide a definitive diagnosis. 
I .4. I1wrapy 
Not only diagnostic methods have changed, also new surgical and therapeutic 
alternatives have been developed, based on the concept that occult metastases 
have already developed in about 50% of the patients at the time of diagnosis, 
independent of lymph node metastasis. Nowadays, breast conserving surgery, 
instead of mastectomy, in combination with axil!ary dissection, followed by 
postoperative irradiation of the thorax wall is generally applied to tumours less 
than 4 cm in diameter. Long term results after 8-10 years follow-up comparing 
the two treatment modalities (that is lumpectomy versus mastectomy) have 
demonstrated comparable disease free survival (DFS) and overall survival 
(OS).38.39,40.41 ln addition, systemic adjuvant therapy is given in node-
positive patients: in general, chemotherapy in premenopausal patients and 
hormonal therapy in post menopausal patients. This approach has been shown 
to improve DFS and OS42 of breast cancer patients. Neo-adjuvant chemothe-
rapy is given to patients with large, skin or thorax wall invasive (T4) 
tumours. 43 
With regard to DCIS new treatment modalities are being proposed. The findings 
of Fisher" and Solin" suggested a beneficial effect of irradiation of the 
thorax in reducing the risk for development of invasive cancer after removal of 
the lesion by lumpectomy. Validation studies of patients with DCIS < 5cm 
being treated with radical excision alone or surgery plus radiation, based on the 
new classification, are under way (EORTC trial 10853). 
Selection for node-negative patients with a poor prognosis is inlportant, since 
in those cases treatment with neo-adjuvant chemotherapy is being proposed. In 
general, many prognostic factors have been studied in relation to the biological 
behaviour of breast carcinomas of which some of the most important wil! be 
mentioned in this introduction. 
2. PROGNOSTIC AND PREDICTIVE FACTORS 
Standard prognostic parameters 
2.1. Age. 
As mentioned before, age specific incidence displays a progressive rise with 
increasing age. Several studies have shown evidence that women < 35 years 
have higher grade primary tumours and poorer 5-year survival than older 
premenopausal women.46.47.48.49 In support of these data Walker et al50 
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demonstrated that breast cancers in this age group had high proliferation rates, 
significantly higher incidence of P53 protein staining and more ER and PR 
negative tumours (see below). 
2.2. TW/IOI/I' slagillg: 11/11101/1' size, lylllph Ilode slall/s alld dislallllllelaslasis. 
Tumour size and axillary Iymph node status at diagnosis are weil established 
prognostic factors for early reeurrence. '1.52.53.54." Lymph node status is 
still the major prognostic indicator with a ten-years survival of Iymph node 
negative patients of 70 % eompared to less than 40 % of node-positive 
patients"·". The number of tumour positive Iymph nodes also influences 
prognosis. Ten-year survival has been reported to be 38 % if one to three nodes 
are positive, and 13 % if four or more nodes are positive.52 Moreover the size 
of the primary breast tumour is correlated to the number of nodes 
involved53.56,57,58. 
Presenee of distant metastases indicates a poor prognosis since no cure is pos si-
bie. However sinee breast eaneer is of ten a slowly growing proeess some 
patients with metastasized disease may live for many years. The prognosis for 
patients with bone and skin metastases tends to be beller than for those with 
visceral metastases". 
2.3. Histological feall/I'es. 
Studies with large cohorts of patients have illustrated the importanee of 
histologie al typing and grading. "'.61.62.63.64.6'.66 Histologieal typing 
identifies three groups of patients with a different biologieal behaviour: 
I. a group with a favourable prognosis (tubular, cribriform and mueinous type 
breast carcinomas), even if the tumour is large, 
2. an intermediate group (lobular, mixed type and medullary type earcinomas), 
3. a high risk group (ductal carcinomas not otherwise specified (NOS)). 
In general, tumours are graded according to BIoom and Richardson"', with 
modifications as described by Elston et al". This system is based on the scale 
of tubule formation, the assessment of nuclear pleomorphism and mitotic rate. 
In multivariate analysis, grading, when the protocol is strictly applied as shown 
by the Nottingham group," is an independent prognostic factor, with Iymph 
node status second in importance. Patients with grade ! tumours have a 
significantly better survival than those with grade II and III tumours. When 
grade and tumour type are used together in combination with the Iymph node 
status,67 the combination of these parameters even more accurately predicts 
prognosis . 
To avoid the subjectivity of visual grading systems semi-automated and 
automated systems for quantitative analysis have been devised. The group of 
Baak68 found the mitotic activity index to be the most accurate single 
prognosticator even more so when combined with Iymphnode status and nuclear 
area (multivariate prognostic index: MP!69). 
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2.4. Steroid receptors 
The development of normal breast glandular tissue and breast malignancies are 
regulated by hormonal factors, affecting cell differentiation and proliferation. 
Estrogens and progesterones mediate their effect on breast glandular epithelial 
cells and carcinoma cells by interactions with their specific (nuelear) receptor. 
Approximately 70% of the primary breast tumours express estrogen receptars 
(ER). Expression of the estrogen-regulated progesterone receptor (PR) in most 
of these tumours indicates that the ER is functional. In primary breast cancer 
hlgh levels of steraid receptars are a favourable prognostic parameter and a 
predictor of response to endocrine therapy. Moreover , tumours containing bath 
ER and PR at diagnosis have a better prognosis and show the highest frequency 
of repOilse to endocrine therapy compared to ER-positive, PR-negative 
tumours.70 Eventually however, response duration to honnonal therapy is 
limited and disease progression occurs in most, initially responsive, patients. 
Regarding the prognostic value of ER and PR in node-negative patients, 
controversy exists. 7I Large studies with long follow-up have demonstrated by 
multivariate analysis that in node-negative breast cancer ER and PR expression 
is a significant prognostic factor of DFS in premenopausal patients, whereas in 
postmenopausal patients such an association was not present. 72.73.74 In spite 
of these controversies, it is elear that patients with steroid receptor-positive 
tumours benefit from adjuvant endocrine therapy". Moreover ER and PR 
measurements will allow us to select patients with recurrent breast cancer who 
are more likely to benefit from endocrine therapy75.,., emphasizing the 
importance of ER and PR measurements in breast cancer. 
The functional role of androgen receptor (AR) expression is less weil defined. 
In vitro studies have suggested that androgen-induced inhibition of cell 
proliferation is AR mediated.,,·n In vivo studies"·800n human breast cancer 
have shown that the combined use of atldrogen and antiestrogen therapy may 
have therapeutic advantages over anti-estrogen therapy only. 
Other estrogen dependent proteins like the estrogen inducible protein pS2, are 
being investigated to assess their predictive and prognostic value. High levels 
of pS2 are related to good survival, the latter especially in the subgroup of 
patients with ER/PR positive tumours. Moreover pS2 has been found to be more 
predictive than biochemical ER measurement for the likelihood of tumour 
response to endocrine treatment. 81 
2.5. Epidermal growth factor receptor 
Not only sex steroid hormones, but also polypeptide growth factors are involved 
in cell proliferation. Thus, epidermal growth factor (EGF) is one of the growth 
factors necessaty for the maintenance of normal breast epithelium and can 
stimulate proliferation of normal mammary epithelium and human breast cancer 
cells in vitro. lts action is mediated by its receptor (EGFR). Approximately one-
third to one-half of the breast tumours express EGFR. An inverse correlation 
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between EGFR and steroid receptor status in primary breast cancer and breast 
cancer cell-lines on the protein and mRNA level has been reported. " Several 
studies have demonstrated that tumours expressing EGFR are more likely to be 
resistant to endocrine therapy81·84. 
2.6. Gel/es illvolved il/ developmelll of allli-esfrogell /'esisfallce. 
Development of endocrine therapy resistance in ER-positive breast callcer is a 
m'\ior problem in the management of patients with recurrent disease. Little is 
known about the mechanisms underlying this progression. It may involve 
alterations in the estrogen-receptor structure and function"and changes in the 
paracrine interactions with the stromal cells". 
Recently it has been proposed (Dorssers et al81•88) that tamoxifen treatment 
resistance might weil be caused by genetic alterations of the tumour cells. So far 
they identified tllree Breast-Cancer-Anti-estrogen-Resistance (BCAR 1,2 and 3) 
loci in a series of tamoxifen-resistant breast cancer cell lines. However, the 
clinical relevance of these resistance genes still needs to be established. 
2.7. Measll/'es of p/'oliferatioll 
The growth rate of tumours is determined by the ratio between tumour cell 
proliferation and tumour cell death as the consequence of apoptosis and 
necrosis. Fast growing tumours are considered to have a worse prognosis89 • 
Mitotic activity, determined by cOUllting mitotic figures, is one way of assessing 
proliferation and is part of the histological grading system, as described before. 
Baak et al" found the mitotic activity index to be the most accurate single 
prognosticator and th is was even shown to be more powerful in combinatioll 
with Iymph node status and tumour size (Multivariate Prognostic Index (MPI)69). 
Proliferation has also been evaluated by determining the fraction of cycling cells 
in S-phase, either using DNA flow cytometry or 3H-thymidine and 
bromodeoxyuridine (BrdUrd) labelling indices. Despite the lack of standardized 
methods of DNA content measurements, an association has been demonstrated 
between increased risk of recurrence and mortality of patients with high S-phase 
fraction with both node-negative and node-positive invasive breast 
cancers. 90•91 •92•93 Likewise the 3H-thymidine and BrdUrd labelling indices 
are found to be independent prognostic factors!'·95." especially in node-
negative patients. Antibodies directed against the proliferating cell nuclear 
antigen (PCNA) which appears in the nucleus primarily during S-phase have 
become available. However, a predictive value of PC NA labelling index for 
clinical outcome has not been found consistently. 97.98.99 
Other monoclonal antibodies such as Ki-67 or MIB-I, defining a proliferation 
associated nuclear protehl have become available, [00 demonstrating cells not 
only hl G I, but also in G2 as weil as in S-phase. These markers are more easily 
applied to and evaluated in tumour tissues and therefore used increasingly in 
clinical studies evaluating growth fractions in relation to other knowll prognostic 
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indicators.10I.J01.JOl·A better estimate of the growth potentialof a tumour 
would be obtained if, next to a measure of proliferation, also apoptosis could 
be quantitated. Currently, DNA fragmentation and the presence of single strand 
ends of DNA can be detected by several in situ assays, employing nich-
translation or terminal transferase. Recent data, however, suggest caution in the 
intelpretation of the outcome of these assays"". 
2.8. DNA-Ploidy 
Gross changes in nuclear DNA content can be measured by DNA flow 
cytometly. DNA-aneuploidy is considered as a reflection of the genetic 
instability of a breast cancer. The percentages of aneuploid breast cancers range 
between 60 and 90. 
Some authors found aneuploidy to be closely related to the clinical outcome in 
breast cancerlo5.I06.107.I08.IO'espeCÎally in node-negative breast 
cancers. I07 However, due to a lack of standardized methods, results are 
somewhat inconsistent. In a consensus review of the clinical utility of DNA 
cytometly in carcinoma of the breast it was demonstrated that DNA index fails 
to achieve independent prognostic significance using multivariate analysis 
because of correlations with more powel"ful prognostic factors"o. 
2.9. Prolo-oncogenes al/d llIIl/OlIr sllppressor gel/es 
Molecular alterations in proto-oncogenes and tumour suppressor genes are 
responsible for the development of cancer. Dominant mutations can activate 
proto-oncogenes to become oncogenes and recessive mutations may inactivate 
tumour suppressor genes. The tumour suppressor gene TP53, located on the 
short arm of clu'omosome 17, has been implicated in the regulation of normal 
cell growth and division, DNA repair and apoptosis. This gene is frequently 
(14-52%) altered in primaly breast cancer and is related to poor DFS and 
OSIII.II2. In general, mutations in the TP53 gene give rise to an altered 
protein which, due to a prolonged half-live is stably expressed at high levels. 
Breast cancers with high expression of TP53 protein are associated with poor 
response to tamoxifen and chemotherapy after relapse. This is reflected by poor 
progression free survivali". Amplification of the oncogene MYC, found in 10-
23 % of primary breast cancers, has also been associated with poor progno-
SiSIIl.I". Since P53 and MYC genes mediate drug-induced apoptosis, the effect 
of P53 or MYC gene alterations may be related to the inhibition of the therapy 
induced apoptosis and therefore promote tumour cell survival. c-Myc 
amplification is a better prognostic factor than HERl2neu amplification in 
primaly breast cancer. 114 Overexpression of HERl2neu protein is found 
predominantly in grade 3 intra ductal carcinomasl15.116 
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2.10. Tissue proleases relaled 10 illvasioll alld melaslasis. 
Cathepsin D is an estrogen indllcible Iysosomal enzyme, which is capable of 
digesting extracellular matrix and also acts as a growth factor. It may therefore 
play a role in determining tumour invasiveness and proliferative activity, both 
indicators of an aggressive biological behaviour of a tumour. Several studies 
have indicated that high levels of catllepsin D are related to pOOl' 
survival! 17,118. 
Recently the Urokinase-type plasminogen activator (uPA) was found to play a 
central role in the multifactorial processes of invasion and metastases by 
activation of plasminogen which is subsequently converted to plasmin. Plasmin 
can activate type IV procollagenase which ultimately lead to tumour cell 
invasion and metastasis. The activity of liP A is enhanced af ter binding to its 
receptor (uP AR) and decreased by its inhibitors plasminogen activator inhibitor-
land 2 (PAI-l and PAI-2). In pre-clinical studies it was demonstra-
ted"9.120.121.122·123that high levels of uPA, uPAR and PAI-l are 
indicative of pOOl' prognosis also in Iymph node negative patients, whereas high 
levels of PAI-2 are associated with a favourable prognosis in patients with 
tumours containing high levels of uPA. Moreover high levels of uPA, uPAR 
and PAl -1, were associated with pOOl' response and survival while high levels 
of PAI-2 were related with prolonged survival and more favourable response 
following tamoxifen therapyl24. A multicenter randomized study of node 
negative patients has been started to investigate the effect of adjuvant 
chemotherapy in patients with high levels of uPA, uP AR and PAl-I. 
The prognostic parameters as described above, can in general also be 
determined using cytological materia!. This holds particularly true for nuelear 
proteins and genetic markers. Grading systems on routinely stained cytological 
preparations have been described125•126and have been found to have 
prognostic value in identifying high grade tumours. Likewise (semi)-quantitative 
studies using morphometry, image-cytometry and tlowcytometry have been 
applied to cytology to measure nuelear size and shape127·128.129 and/or 
DNA contentI30.131 , with results similar to those fOUlld in histology. 
3. PHYLLODES TUMOURS OF THE BREAST 
3.1. IlIIroduclioll 
Not only neoplasms of epithelial origin, but also benigll and malignant stromal 
tumours may develop in the breast. 
One type of stromal neoplasm, the so called phyllodes tumours, is of particular 
interest, sillce none of the histological criteria used to categorize these tumours 
as benign or malignant, are effective in predicting local recurren-
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ce132. 13'. 134. In contrast to breast carcinomas phyllodes tumours are 
uncommon. Only 0.3-0.5% of breast tumours in females belong to this group. 
The majority of cases occurs in women between ages of 35 and 55 years, the 
average age being around 50 years. 
3.2. Histological featllres 
Like fibroadenoma, phyllodes tumours are histologically characterized by a 
combined proliferation of stromal cells and ductal epitheliumI35. The stromal 
component determines the biological behaviour of the tumour. Macroscopically 
they form lobulated firm masses, microscopically the tumour shows cystic 
spaces lined byepithelium, in which the stroma classically projects in a leaflike 
fashion. Cytological specimens of these tumours are characterised by branching 
epithelial cell groups, higWy cellular stromal fragments and fibroblasts in the 
backgroundI36.J37 • The tumour is classified according to the histological 
features of the stromal component: stromal cellularity, nuclear atypia and 
mitotic activity; stromal overgrowth, necrosis and heterologous elements. 
Arollnd 20% of phyllodes tumours are considered malignant on the basis of 
these histological criteria. Due to the higWy cellular stroma benign phyllodes 
tumours are often mistaken as fibroadenomas both in cytology and histology. 
3.3. T71erapy 
Wide excision with a 10 rum margin of surrounding normal breast is 
recommended. Since some of them are clinically mistaken as fibroadenoma, the 
initial excision is often inadequate. Mastectomy is considered to be the treatment 
of choice for those women with a very large benign tumour or with malignant 
lesions. No axillary lymph node dissection is needed, since metastasis is almost 
exclusively haematogenous. 
3.4. Prognosis 
The presence of tumour at the margins of the excised specimen is found to be 
a major determinant of local recurrence, moreover histological characteristics 
have only limited prognostic significance.134.I35.136. 
4. AIM OF THE STUDY 
Up till now most studies evaluating cell biological markers like ER and PR have 
used biochemical assays. Since these methods require analysis of tissue 
homogenates, they do not give insight in the expression pattern of these markers 
at the cellular level. With the development of immunohistochemical techniques 
tumour markers can be directly visualized at the cellular level and consequently 
the distribution of prognostic markers in normal and malignant breast tissues can 
be estimated. The decreasing size of the tumours, and new treatment modalities 
together with an increasing demand of biological markers, makes the application 
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of immunohistological techniques even more appealing. The method is rapid, 
requiring a minimum amount of tissue: which permits its application even on 
FNA material. Good correlations between most biochemical, 
immunohistochemical (!H) and immunocytochemical (IC) assays have been 
reportedJ38 ,i39,140,141,142, although discrepancies partly related to 
contamination with benign epithelium in the biochemical samples, and partly to 
heterogeneity of the tumour, loss of antigenicity and differences in teclmiques, 
mayexist. 
One of the purposes of this thesis was to investigate the feasibility of the use of 
promising immunohisto- and cytochemically determined cell biological markers 
in FNA material and frozen tissue samples, and to analyze their relation to 
clinical and histological variables in breast tumours. Furthermore, we wanted 
to enhance the quality of immunocytochemistry by developing a quality assured, 
standardized method of immunostaining, Finally we wanted to evaluate whether 
the detection of TP53 gene mutations would offer new prognostic information 
in phyllodes tumours of the breast. 
In chapter 2 we evaluated the feasibility of the lIse of Ki-67 assessed 
proliferative activity in FNA smears, obtained from benign and malignant 
tumours as wel! as from loco-regional and distant metastases and detennined the 
relationship with clinical parameters, 
In chapter 3 we compared the results of the Ki-67 determined growth fraction 
in FNA smears and cryostat sectiolls of correspondillg tumours. In addition we 
illvestigated the associatioll betweell different histological subtypes and the level 
of Ki-67 reactivity, 
In chapter 4 we report on a study to determine the best standardized method for 
material processing and IC staining of prognostic markers in FNA specimens of 
breast carcinomas, 
In chapter 5 we investigated estrogen, progesterone and androgen receptor 
expression in breast cancel' patients by IH on snap frozen tissue specimens. 
Expression of AR was compared with that of ER and PR as weIl as with tumour 
grade and age. 
In chapter 6 the prognostic value of AR was analyzed in a retrospective study 
of 153 breast carcinomas of which the clinical, histologie al and !H determined 
cel! biological data were recorded and examined in an uni- and multivariate 
analysis. 
In chapter 7 the relation between cel! biological markers and the biological 
behaviour of a case of a malignant phyllodes tumour, was studied, Expression 
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of Ki-67, TP53 and its regulated proteins, like MDM2, P21, BCL2 and BAX, 
in the primary, recurrent and metastatic tuIllour tissue was studied using IH and 
Illolecular biological techniques. 
Chapter 8 gives a general discussion of the results of the studies described in 
this thesis and general conclusions are drawn. 
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CHAPTER 2 
SHORT COMMUNICATION 
IMMUNOCYTOCHEMICAL STAINING OF PROLIFERATING CELLS IN 
FINE NEEDLE ASPIRATlON SMEARS OF PRIMARY AND METASTATIC 
BREAST TUMOURS 
V. Kllenen-Bollmeester, D.1. Blonk and Th.R. Van der Kwast 
Br J Cancer, 57: 509-511, 1988 
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SHORT COMMUNICATION 
The variability in biological behaviour of breast carcinomas is a long standing 
problem. Lymph node status is still the major prognostic indicator (Fisher et al 
1983), but also mitotic activity appears to be of considerable prognostic 
relevance, either as a single parameter (Schiodt 1966; Stenquist et al 1981; Baak 
et al 1985), or as part of histological (BIoom & Richardson 1957; Elston et al 
1982) or cytological (Mauriquand et al 1986) grading. Since only a minor 
fraction of proliferating ceUs is in mitosis, the determination of the total number 
of proliferating ceUs could be a better indicator of the growth fraction of a 
tumour population and therefore might give more information about the 
biological behaviour of a tumour. 
A mouse monoclonal anti body (Ki-67) has become available defining a nuclear 
antigen present in proliferating ceUs throughout the ceU cycle. The antigen is 
absent in GO and early GI (Gerdes et al 1983,1984). Thus, Ki-67 enables the 
immunocytochemical detection of cycling ceUs without the need of external 
admirtistration of radioactively labeUed nucleotides or mutagertic substances such 
as bromo-deoxyuridine or iododeoxyuridine. Until now studies on breast 
tumours using Ki-67 as a proliferation marker were perfornled on histological 
material. As fine needIe aspiration (FNA) smears are more and more used as 
diagnostic tools, we investigated the feasibility of the use of this monoclonal 
antibody on cytological material obtained from benign and malignant tumOlIl'S 
as weU as from distant metastases of breast carcinomas. In addition, a possible 
relationship between the Ki-67 determined growth fraction of breast carcinomas 
and clinical parameters such as tumour size, Iymph node status and menopausal 
status was investigated. The material consisted of FNA smears of 38 breast 
carcinomas (31 invasive ductal, 5 coUoid and 2 meduUary carcinomas), 20 
fibroadenomas and 26 metastases ofbreast carcinomas (161ymph nodes, 2liver 
metastases and 8 local recurrences); the ceUularity of aspirates from metastases 
and primary carcinomas was comparabie. The air dried smears were fixed in 
acetone for 5 min and immunostairting with the mouse monoclonal antibody 
Ki-67 (Dako, Denmark) diluted 1:10 in PBS, pH 7.4, containing 0.05% gelatin 
and 0.1 % NaN3, was performed using the indirect conjugated 
immunoperoxidase method as described previously (Van der Kwast et al 1985). 
After addition of diaminobenzidine as substrate brown speckled staining of 
nuclei or nucleoli was considered as a positive reaction with Ki-67. Mitotic 
figures were also stained. Nuclear counterstaining was achieved by a 1 min 
incubation in Mayer's haematoxylin (Figure 1). The percentage of Ki-67 
positive nuclei was determined by counting 500 ceUs at a magrtification of 
1000 x. The counting was done by a cytologist (VK) and care was taken to 
count tumour ceUs only or in the case of benign tumours to count breast 
epithelial eeUs only. The clinical data coUected from the patients with the 
primary tumours are shown in Table l. 
Table I. Clinical data of 38 patiellfs witl! primary breas! carcinomas 
Pre Post TI TI TI TI T4 N? No NI 
10 28 2 11 18 3 4 3 14 11 
Total 38 38 
Pre/Post=pre/postmenopausal T?=Unknown; N?=Unknown. 
Figure 1. Picture of FNA smear of breast carci110wo, showillg 
Ki-67 slatlIed nuclei (arrows). 
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N2 
10 
38 
The FNA smears of the benign tumours contained a low percentage of 
immunostained nuclei, ranging from 0.0-6.7 with a mean of 1.1 and a median 
of 0.4. In contrast only four of the malignant tumours showed a percentage 
below 2, 21 between 2 and 10, and 13 even higher than this (Figure 2) with a 
mean of 10.5 and a median of 7.9. In comparison with the malignant primary 
tumours the metastases revealed even higher values with a mean of 14.3 and a 
median percentage of 12.3. The difference of the last two median values, 
assessed by the Whitney-test was statisticaUy significant (P <0.05). 
Assessment of the Ki-67 determined proliferative tumour ceU fraction in FNA 
smears of malignant breast lesions led to essentiaUy similar results as recently 
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reported in several studies (Gerdes et al 1986; lelie et al 1987; McGurrin et al 
1987; Barnard et al 1987) of Ki-67 determination on cryostat sections of breast 
tumours (Tabie II). 
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Table 11. Reported data ofmeall percentages of Ki-67 sloilled nuclei 111 primor)' breas! carcillomas 
ill cryostat secfÎ011s olld Êmprillls/FNA smears. 
Histology Cytology 
Gerdes 16.6 
Lelie 16.2 14.5' 
McGurrin 22.0 
Barnard 20.6 
This study 10.5' 
lImprints; bFNA smears 
It appears from the data in Table Il that the Ki-67 percentages of eryostat 
sections tend to be higher than those of the aspirates. This lower figure in 
aspirates may be explained by sampling differences. When the tumour is 
aspirated the material is derived from both peripheral and central parts of the 
tumour, whereas a cryostat section gives infonnation on one part of the tumour 
only. 
Aecording to Baak et al (1985) and Van der Linden et al (1987) the mitotic 
activity index in histologie al material is the strongest independent prognostie 
factor in their group of patients both retrospectively and prospeetively. Although 
the prognostie significance of the Ki-67 determined proliferative tumour cell 
fraction remains to be proven, we think that determination of the total cycling 
fraction of a tumour gives more information about prognosis than assessment of 
numbers of mitotic figures alone. This holds especially true for FNA smears, 
since they rarely contain mitotic tumour cells. Further support for the hypothesis 
that the Ki-67 determined proliferative fraction may be of prognostic relevanee 
can be drawn from the in vitro 3H-thymidine labelling studies of Meyer et al 
(1983) and Tubiana et al (1984). These authors incubated small specimens of 
freshly obtained breast tumour tissue with 3H -thymidine and eounted the number 
of labelled nuclei from autoradiographed microscopie sections.ln the study of 
Meyer et al (1983) with a follow-up period of 4 years both the lymph node 
status and the 3H-thymidine labelling index appeared to be the strongest 
independent indicators of early relapse. In the long-term prospeetive study of 
Tubiana et al (1984) the 3H-thymidine labelling index appeared to be the most 
predietive independent indicator with respect to relapse-free survival and total 
survival. It should be noted that Ki-G7 llll1llunostaining is onIy indirect evidence 
of proliferation while the mitotie index and 3H -thymidine incorporation directly 
relate to proliferative activity. Furthermore Ki-67 stains cells in G l-phase, cells 
arrested in this phase of the eell cycle mayalso be stained by Ki-67 whieh leads 
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to an overestimation of the fraction of actually proliferating cells. In contrast to 
the findings of Lelie et al (1987), but in agreement with the study of McGurrin 
et al. (1987) and Barnard et al (1987), we found no relation between lymph 
node status and percentage of Ki-67 labelled tumour cells. Neither did the 
'H-thymidine labelling studies (Meyer et al 1983; Tubiana et al 1984) show any 
relation to lymph node status. 
No clear-cut correlation was found in this study between tumour size and 
menopausal status or percentage of Ki-67 innnunostained nuclei. Probably the 
number of investigated tumours was too low to establish such a relationship. 
It was interesting to see, however, that the really high values (above 40% see 
Figure 3) were only seen in premenopausal women. In addition, the two highest 
values (30.5% and 19%) in the group of postmenopausal women were 
medullary carcinomas. It is 1a1Own that the latter tumours have a high mitotic 
activity and display a different biological behaviour than the infiltrating duet 
carcinomas (Azzopardi, 1979). 
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Our observation of significantly higher percentages of Ki- 67 labelled tumour 
cells in metastases compared to primary carcinomas may point to two 
possibilities: tumours with a higher proliferative activity may tend to a more 
aggressive biological behaviour, or the higher proliferative activity of 
metastasized tumour cells is caused by a more favourable environment. In 
support of the first possibility is the prospective study of Tubiana et al. (1984) 
which showed that the 'H -thymidine labelling index is related to the probability 
of metastatic dissemination. In addition, Meyer et al (1983) showed that the 
'H-thymidine labelling index of primary breast tumours and their corresponding 
axillary metastases were not significantly different. Thus, it seems unlikely that 
the higher proliferative activity of metastasized tumours can be attributed to 
microenvironmental influences. Nevertheless, it would be interesting to compare 
the Ki-67 immunostaining results of the aspirates of the primary tumours and 
the metastases from the same patient. Further studies are indicated to 
demonstrate the prognostic relevance of the imnllmocytochemical assessment of 
Ki-67 determined proliferative fraction of tumour cells in FNA smears. 
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CHAPTER 3 
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3.1 ABSTRACT 
Thirty four cases of invasive breast carcinoma \Vere analysed for heterogeneity 
of Ki-67 reactivity in a tumour, and proliferative activity in various histological 
subtypes \Vas compared. The growth fractions determined in areas of central and 
peripheral tumour were the same. Mucinous and lobular carcinoma showed 
lower Ki-67 activity than ductal carcinomas. When ductal carcinomas were 
subdivided according to their dominant growth pattern, the carcinomas with a 
solid or comedo growth pattern showed the highest proliferative activity. These 
results largely confirm data from previous cell kinetic studies on the 
incorporation of radioactively labelled thymidine. A correlation between the 
growth fraction determined by Ki-67 in fine needIe aspiration smears and 
cl-yostat seetions of eorresponding tumours was shown, implying that the 
immunostaining of eytological smears gives areliabIe impression of the growth 
fraction of a tumour and may therefore be used in prospective studies. 
3.2INTRODUCTION 
Cell kinetic studies have shown that there is an association between the 
thymidine labelling index and the biological activity of breast carcinomas (1,2). 
Monoclonal antibody Ki-67, which defines a nuclear antigen in proliferating 
cells, allows eells in the growth eyele to be deteeted without the need for time 
eonsuming methods sueh as external applieation of radioaetively labelled 
nucleotides or mutagenic substances sueh as bromodeoxyuridine or 
iododeoxyuridine (3). This antibody is therefore used inereasingly in studies on 
breast carcinoma to evaluate the growth fraction in relation to other known 
prognostic variables both in histological and eytological material (4-9). 
As assessment of the growth fraction determined by Ki-67 immunostaining may 
be implieated in the prognosis of a patient it is essential to follow standardised 
procedures. Beeause it is not known to what extent discrepant data may arise 
due to heterogeneity of the distribution of proliferating cells in a tumour, we 
assessed the prevalence of Ki-67 positive cells in the peripheral and central areas 
of the tumour. Furthermore, we determined the association between different 
histologieal subtypes and the level of Ki-67 reactivity. 
Beeause fine needIe aspiration (FNA) smears are increasingly being used in the 
diagnosis of breast carcinoma and consequently for immunoeytochemical 
analysis, we assessed the reliability of Ki-67 immunostaining of FNA smears, 
by comparing the results found in histological sections with those found in 
eytological smears of the same tumour. 
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3.3 METHODS 
Thirty four cases of invasive breast carcinoma were evaluated. The tumours 
were c1assified according to the WHO c1assification (10). They included 21 
ductal, six lobular, four mixed type (ductal/lobular) and three mucinous 
carcinomas. The 21 ductal carcinomas were consecutively c1assified according 
to the dominant growth pattern: two cribrifonn, three solid, four comedo, two 
mixed solid/comedo and 10 not otherwise specified (NOS). The comedo carci-
noma was defined as a ductal in situ component in an otherwise invasive 
carcinoma. 
A complete cross-section of resected tumour was snap frozen in liquid nitrogen. 
The areas of central and peripheral tumour were assessed separately. 
Frozen tissue samples on glass slides coated with poly-L-Iysine (11) and FNA 
smears on uncoated glass slides were air dried and subsequently fixed in acetone 
(for 10 minutes). Af ter rinsing in phosphate buffered saline (PBS) Ki-67 (Dako, 
Denmark) was applied (dilution 1 in 5 in PBS with 0.02 % gelatine, one hour). 
After rinsing with PBS a horseradish peroxidase conjugated polyclonal rabbit 
anti-mouse antibody (Dako, Demnark) was used as second step reagents for half 
an hour. After rinsing with PBS the reaction product was visualised using 
diaminobenzidine as substrate. After a final wash nuclear counterstaining was 
achieved by incubation in Mayer's haematoxylin for one minute. Positive and 
negative controls were included. Brown speckled staining of nuclei or nucleoli 
was regarded as a positive reaction. This positivity was semiquantitatively 
assessed in tissue sections by counting at least 300 cells in the areas with highest 
proliferative activity, similar to the procedure described for mitotic 
counting(12). In 26 cases this was done both in the central and peripheral areas 
of the tumour specimen. 
When the invasive ductal carcinomas showed special growth patterns, these 
were counted separately. In FNA smears 500 cells were counted at random at 
a magnification of 1000 x under oil immersion and the percentage of positive 
nuclei was determined (8). The Ki-67 score of 14 FNA smears was compared 
with that of the frozen sections of corresponding tumours. 
3.4 RESULTS 
In 26 carcinomas the Ki-67 reactlvlty was assessed both in the central and 
peripheral areas of the same tumour. Although the central areas on average 
reached somewhat higher values than the more peripheral ones, astrong 
correlation (0.78) between the two areas was seen (fig 1). 
Figure 2 shows the Ki-67 reactivity of the 34 carcinomas c1assified according 
to the WHO. The mucinous carcinomas contained a low percentage of Ki-67 
stained nuclei, with a mean of 10%, whereas the ductal carcinomas showed 
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much higher values, with a mean of 23 %. The lobular and mixed carcinomas 
showed intermediate values of 18% and 15%, respectively. 
Figure 2C shows the Ki-67 determined growth fraction of the ductal carcinomas 
according to their dominant growth pattern. Comedo and solid growth patterns 
sIlOwed mean values of Ki-67 staining of33% and 31 %, respectively. The NOS 
carcinomas showed a mean value of 19 %. Of the two ductal carcinomas with 
a dominant cribriform growth pattern, one showed no reactivity at all, whiIe the 
other one showed Ki-G7 staining of 10 %. In 14 carcinomas the Ki-G7 reactivity 
in FNA smears and frozen tissue sections of the same tumour correlated (0.71) 
(fig 3). In FNA smears on average lower Ki-G7 values were obtained than 
sections of corresponding tumours. Nevertheless, a high score on FNA smears 
was usually associated with a high score on frozen sections (fig 4). 
Figure 3. Correlatioll between the Ki-67 delermilled 
gro}vtl! [raet/oll assessed in frozell sectioJ/s alld in fine 
lIeedle aspiratioll SlJleflrS of file same lfImour (11 = 14) 
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3.5 DISCUSSION 
This study shows that similar levels of Ki-67 immunostaining are found both in 
central and peripheral areas of the tumour (fig 1). This result is at variance with 
the understanding that most cellular areas, and therefore the areas where active 
growth is most likely, are normally found at the periphery of a tumour (12,13). 
In our view this only holds tlUe when the central area of the tumour is highly 
sclerotic due to pOOl' vascularisation. 
In this series the four histological types of breast carcinoma displayed different 
proliferative activity as defined by Ki-67, the ductal carcinomas showing the 
Wghest activity, the mucinous the lowest. This agrees with published findings 
(14-17), which state that ductal carCÎnomas are the most aggressive tumours 
compared with lobular and muCÎnous carcinomas, the latter two being slowly 
proliferating invasive carcinomas with a long survival. Similar results were 
obtained in the cell kinetic studies done by Meyer (1), where both lobular and 
muCÎnous breast carcinomas showed low thymidine labelling indices. 
Furthermore, LelIe et al compared the growth fraction, as determined by Ki-67, 
of ductal and lobular carcinomas and found lower values in the latter (6). 
The various growth pattel'l1s of the invasive ductal carcinomas also show large 
differences in their proliferative activity (fig 2C). The two cribriform 
carcinomas showed the lowest levels of Ki-67 immuno-staining. SinlÎlarly, 
Meyer observed low thymidine labelling indices in the intraductal carCÎnomas 
with a cribriform growth pattel'l1 (18). The same carcinomas have an excellent 
prognosis (16,19). In contrast, the in situ comedo component in otherwise 
invasive ductal carCÎnomas silOwed high levels of Ki-67 inununostaining 
comparable with the high thymidine labelling indices in intraductal comedo 
carCÎnomas (18). Surprisingly, we found similar values both in comedo and solid 
carcinomas; Meyer observed low labelling indices in solid intraductal 
carcinomas cOlllparable with the ones found in cribrifol'ln intraductal 
carcinolllas. 
Like LelIe et al we observed, on average, lower Ki-67 scores in FNA smears 
than in frozen sections (6). This may have been due to a different sampling and 
counting method. Using fine needie aspiration, cells are obtained from all parts 
of the tumour and counting is done randomly; frozen sections give information 
about only one part of the tulllOur and proliferative activity is determined by the 
areas with highest activity. Consequently, slllears may give a better illlpression 
of the average proliferative activity of a tumour than histological sections. 
Our results on breast cancel' are in line with those found by Brown et al (20). 
These authors cOlllpared cryostat sections of non-Hodgkin's lymphomas with 
FNA smears of corresponding tunlOurs and found an excellent correlation. 
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Early detection of breast cancer as a result of screening programmes will result 
in smaller amounts of malignant tissue available for additional techniques. The 
feasibility of immunocytochemical detection of proliferative activity on FNA 
smears shown here allows the prognostic markers on these small sized tumours 
to be assessed. 
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CHAPTER 4 
IMMUNOCYTOCHEMICAL DETECTION OF PROGNOSTIC MARKERS 
IN BREAST CANCER. TECHNICAL CONSIDERATIONS. 
V Kuenen-Boumeester MD, A.M. Timmermans, E.M.C.A de Bruijn and 
S.C. Henzen-Logmans MD PhD. 
Submifted 
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4.1 ABSTRACT 
The purpose of this study was to establish a good technical procedure for 
immunocytochemical (IC) staining of prognostic markers in breast cancer 
spechnens. The influence of various preparation, fixation and storage me-
thods on ER, P53 and Ki-67 IC staining was assessed, using cells of two 
breast cancer cell lines T47D (ERfP53 +) and ZR-75-ER (ERf +, P53-). In 
addition we searched for a suitable transport medium. Depending on the 
technical procedure, great variations in expression of the tested antigens were 
found. Cytospins fixed and stored according to the Abbott method gave the 
best resuIts. Histocon appeared to be the medium of choice. A good concor-
dance of IC and itrnnunohistochemical (IR) resuIts was found when the 
adopted method was tested on material of 10 breast cancers. This study 
underlines the hnportance of quality coutrolled standardization of cell proces-
sing, fixation and storage of FNA aspit'ates in order to obtain reproducible 
and consistent IC resuIts. 
4.2 INTRODUCTION 
The use of hnmunocytochemistry in the examination of fine needie aspirates 
(FNA's) of breast tumours has enhanced the diagnostic possibilities especially 
with regard to the assessment of prognostic markers. Up til! now most pro-
gnostic markers, like estrogen receptor (ER,), Ki-67 and P53, also known as 
TP53 , are being biochemically and/or itmnunohistochemically assessed on 
tissue spechnens obtained at surgery. However, early detection of breast 
cancer due to breast cancer screeniug programmes has led to reduction of the 
size of breast carcinomas (1) aud therefore to a reductiou of the amount of 
tissue available for diagnostic and prognostic information. In addition, new 
treatment modalities, like neo-adjuvant chemotherapy for T4 tumours, neces-
sitate the maximUIn yield of information from cytological specimens. Good 
correlations between biochemical, histological and cytological assays have 
been reported (2,3,4). Nevertheless discrepancies, due to heterogeneity of the 
tumour and to methodologically differences, may exist. Here we describe a 
study to establish a suitable technical procedure for inllllunocytochemistry 
(IC) of FNA material especially with regard to nuclear antigens. We compa-
red the influence of various preparation, fixation and storage methods (study 
A). We made an assessment of the influence of transport media on quality of 
inununostaining (study B). Finally we compared IC staining of eell material 
and frozen tissue samples of eorresponding breast caneers, using the eell 
material processing technique and transport medium of ehoice (study C). 
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4.3 MATERIAL AND METHODS 
Study A: Thc illfluence of various preparatioll, fixation and storage me-
thods on IC staining rcsults. 
Cell-lines T47D (ER+, P53+) and ZR-75-ER (ER+, PR-) were used for 
this study. Cells were harvested, pelleted by centrifugatioll and resuspended 
in RPMI 1640 medinm. 
I. Cell preparatioll 
Two methods of cell preparation were compared: 
1. A standardized method used to prepare serous effusions as described 
before (5). In short: Cell suspensions were dilutcd with 1 % BSA/PBS, pH 
7.4. Af ter centrifugation (5 min at 2000 rpm) and decanting, the pellet was 
Iysed and fixed at 4 ° C for 10 minutes by adding 2.5 mi lysis buffer contai-
ning isotonic ammonium chloride (4.5 g NH4CL Merck, Gennany), 0.5g 
KHC03 (Merck» and 0.0186 g EDTA (Merck) dissolved in 500 mi aqua 
bidest, Ph 7.4; and 2.5 mi 4% paraformaldehyde (PFA) Merck). The cells 
were rinsed in PBS, followed by centrifugation and decanting. Then the 
pellet was resuspended and diluted in BSA I % in PBS and adjusted to a cell 
concentration of Ix 10' cellIml using a Bürker cell counting chamber (Optik 
Labor, Bad Homburg, Germany) to obtain reproducible specimens with 
optimal cell density. Finally, cytocentrifuge samples were made by centrifu-
gation at 700 rpm for five minutes using a Shandon cytospin 2 (Astmoor , 
Runcorn Cheshire, England). The processed slides were air dried for a maxi-
mum period of five minntes. 
2. The same as protocol I, but without Iysing and fixation of the pellet. 
11. Fixa/ioll alld s/orage 
Different procedures were compared: 
a. No fixation of processed slides. The slides were kept at room temperature 
(RT) overnight. 
b. Fixation of cytospins with 4 % paraformaldehyde followed by methanol/ 
acetone at -20°C ( Abbott method). 
c. Fixation by methanol/acetone only . 
d. Cytospins directly stored at -80 oand fixed afterwards according to either 
method b or c. 
(see table I for exact procedures) 
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Table I. Fixatioll alld storage protocols (sllldy A 11) 
Method 
a 
b 
c 
ct 
Fixationlstorage 
air-dried 
Paraformaldehyde4 % 
PBS 3X 
Methanol 
Acetone 
Storage medium 
methanol 
acetone 
storage medium 
directly stored at 
direct fixation upan 
Temp 
RT 
RT 
- 20' C 
- 20' C 
- 20 0 C 
- 20' C 
- 20' C 
- 20' C 
- 80' C 
thawing followed by method b or c 
III. 11II11I1IIlocylochel1liS/ly 
Time 
overnight 
10 minutes 
10 minutes 
3 minutes 
1 minute 
3 minutes 
1 minute 
The non-fixed slides were fixed in acetone for 10 minutes prior to incubati-
ons and together with the prefixed cytospins rinsed in phosphate- buffered 
saline (PBS), pH 7.4, followed by pre-incubation using 1 % BSA diluted in 
PBS for 10 minutes. The antibodies raised against ER (!D5, Dako, Glostrup, 
Denmark), Ki-67 (MIB-l, 1l1I1nunotech/ Coulter, Westbrook, Maine, USA) 
and P53 (1801, Oncoscience, Cambridge, Mass, USA) were used for this 
study and diluted in 1 % BSA in PBS. Incubation was carried out for 60 
minutes at RT. The APAAP technique (Dako, Glostmp, Denmark, working 
dilution 1:20) was applied after incubation with the linking antibody (Ab)(w-
orking dilution 1 :20 in 5 % NHS in PBS) for visualising the primary antibo-
dy . All immunostained slides were counterstained with Mayer's haematoxylin 
(Klinipath, Duiven, Holland) for 1 min. Slides of eell-lines were included as 
positive eontrols; as negative eontrols the primary antibody was replaeed with 
1 % BSA diluted in PBS in each mn. 
Study B 
The influence of transport media on IC reslllts. 
The following media were compared: 
1. RPMI-1640 containing phenol red, 21 mM HEPES, 10 mM NaHC03, 4 
mM glutamine, 100 U/mi streptomycin, 100 ml'/ml penicillin, 45 I'g/ml 
gentamycin, 10 I'g/ml porcine insulin, 5 I'g/ml insulin, 2.5 I'g/ml estradiol 
and 10% bovine calf semm (heat-inactivated). 
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2. RPMI 1640 supplemented with 10% Foetal calf selUm (FCS) heat inacti-
vated, 20.000 IE penicillinlstreptomycinl L, 20.000 IE Heparin slllphate/L, 
L-glutamine 300mgll, Gibco BRL (Breda, the Netherlands). 
3. PBS/BSA 1 %, pH 7.4% 
4. Histocon ( Polysciences, Warrington USA) 
Cell material of histoiogically proven breast carcinomas was obtained by 
scraping a scalpel blade firmly against the carcinoma and by directly deposi-
ting the material in the media. Cell specimens were prepared according to the 
best method of study A (see results). The influence of the various media on 
IC staining was determined. 
Study C 
Comparison of immunostaining of cytological and corresponding histolo-
gicai specimens. 
Frozen tissue samples and cell scrapings of ten histologically proven breast 
carcinomas were obtained. Cryostat sections (4 I'm thick) were fixed in 
formalin 4 % for 10 min. Cell material was suspended in the chosen transport 
medium of study Band cytospins were prepared according to the adopted 
method of study A (see results). Immunostaining of cytospins and cryostat 
sections was performed using the aforementioned technique, using the antibo-
dies anti-ER, anti-P53 and Ki-67. 
Quall/ifica/ioll 
Frozen material: The percentage of IH assessed ER, and P53 stained tumour 
cells was calculated by scoring the number of positive cells semiquantitatively 
in a total of 300 cells in three different areas of the tumour section (6). The 
Ki-67 score was assessed by counting 300 cells in the areas with the highest 
activity as described previously (6,7). 
Cell material: The ER, Ki-67 and p53 score was assessed by counting at 
random 500 cells as described before (7). 
The IC and IH scores were compared. 
4.4 RESULTS 
Study A 
Ma/erial processillg alld fixa/ioll: 
Variations in staining intensity between the two preparation methods were 
seen. In general cell preparation method A.I.l (prefixation of the cell peIle!) 
showed little or no nuclear staining, in contrast to the strong staining of 
method A.I.2 (fixation of cytospins) (fig I A, B). 
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Figure 1. hifluellce of cell processing 011 P53 lmmlias/aillillg. 
A: PrejixotioJl of suspensiOll witll 4% paraformaldehydefollowed by fixa/ioll alld storage 
of the air-dried cytospill aecordtlJg to file Abbott method 
B: Fixatiotl alld storage of air-dried cytospill accordillg 10 file Abbott met/wd. 
A rapid loss of antigenicity was seen when the cytospins were kept at RT for 
longer than five minutes. Direct freezing of the cytospins before fixation 
folIowed by direct fixation upon thawing according to the various tested 
methods gave inconsistent resllits. eeII processing method A.1.2, folIowed by 
fixation and storage of the cytospins according to the Abbott protocol gave 
the best resllits (demonstrated in fig 2A, Band Table JI). 
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Table 11. Imlllll1lOSwillillg of eell specimens of lwo celflines using variOfls fixatives, prepared 
aecord/ng fo preparati011llletlzod A.I.2. 
ER Ki-67 
A B A 
fixation/storage 
a +/-
b ++ ++ ++ 
c +/- + +/-
d+b* +/-
d+c* 
A: Cel/-fille ZR-75-ER (ER +. P53-) 
B: Cel/-fille T47D (ER +. P53 +) 
me/hod a: air-dried/RT overtligllt 
B 
+1-
++ 
+ 
+/-
P53 
A B 
+/-
+++ 
+ 
+/-
lllelllod b: 4% para formaldehyde + lIletlwllol/acetOJle (Abholt melhad) 
method c: lIletlwllol/acetone 
me/hod d: -BO°C 
* only tested witlt cell-lille T47D 
Table III 
A comparisotl of IC remlts of cellmoterial of a Ilistologicafly proven ER/PS3 + breasf concer, 
slispellded ill d(fferent transport media alld prepared accordillg 10 t/ze adopted met/wd. 
ER 
P 53 
Ki-67 
Sludy B 
medium 1 medium 2 1 % BSA Histocon 
+/- +/-
+/-
++ 
+ 
+ 
++ 
+ 
+ 
Morphology and immunoreaetivity of eells was best preserved when transpor-
ted in either Histoeon or I % BSA (Tabie III). 
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Figure 2. :lnfluellce of differelll storage alld fixalioll methods 011 PS3 imllllillostaillillg 
A: Fixatioll alld storage of air-dried cytospills accordillg to f/ie Abboft method 
B: Storage at -BO°C, followed by fixa/ioll witlt para formaldehyde 4% 
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Study C 
The ten earcinomas deillonstrated a good eorrelation between the IH staining 
of frozen material and IC staining of eOlTesponding eell Illaterial, sllspended 
in Histoeon and proeessed aeeording to method A.I.2 and fixed following the 
Abbott Illethod (fig 3A, Band Table IV). 
Table IV. Percentages of positi~'e lH/IC slab/cd cells in frozell tissue samples af/d correspondillg 
C)'tospillS of feil brensI cOllcers. 
ER P53 Ki-67 
% % % 
sample hist cyl histo cyl histo cyl 
40 
50 <10 <10 50 50 
2 100 100 100 100 50 40 
3 0 0 0 0 40 50 
4 60 60 <10 <10 40 40 
5 0 0 90 90 80 70 
6 80 70 <10 0 30 20 
7 30 40 0 <10 0 <10 
8 50 30 0 0 40 20 
9 80 80 30 30 10 <10 
10 < 10 <10 0 0 10 <10 
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Figure 3.: Comparisoll of P53 immullostaining of cytogical Gild correspoJlding histological 
specimens of a breast carcinoma. 11/C cylospifls are prepared, fixed alld stored according to fhe 
clIOsen me/hod. 
A: Cytospill 
B: Frazell tissue sample 
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4.5 DISCUSSION 
In the fnture IH examination of material obtained at snrgery may partly be 
replaced by IC examination of needie aspirates, and therefore methods of 
investigating prognostic indicators on cytological specimens will expand. In 
an earlier study (8) we demonstrated that with regat·d to serous effusions, the 
most consistent immunostaining was found when lysis and prefixation of the 
material was applied (see method AI.I). In this study however, cell proces-
sing method ALl gave inferior IC results when compared to method AI.2 
(see fig IA,B). This may well be explained by the fact th at nuclear antigens, 
like we studied, require different methods of preparation in comparison to 
cytoplasmic and membrane-boulld antigens (9,10), in general identified in 
serous effusions. Therefore, prefixation of the pellet in method A.I.I, excel-
lent for IC staining of effnsions, gave poor results when nsed for staining of 
nuelear antigens. 
In keeping with other reports (11,12), we observed a rapid detoriation of the 
illllnunoreactivity of the nuelear antigens af ter storage of air-dried slides at 
RT for more than five minutes. In contrast to these findillgs, Suthipintawong 
et al (13) who kept the air-dried smears at RT for up to one week did not 
observe any detoriation of IC staining. Here again the localisation of the 
studied antigens, nuelear antigens versus eytoplasmic/membrane-bound anti-
gens respectively, may weil explain this discrepancy. 
In the experience of Dowell and Burton (11,12) staining results were not 
affected if the specimens were stored unfixed at -70°C and fixed immediately 
up on thawing. Applying this method, we observed negative/weak staining 
(Fig. 2A, B). A possible explanation for these negative results may be that 
due to our working situation (freezer located in other room) the air-dried 
cytospins were not directly frozen, nor fixed immediately upon thawing, 
resulting in loss of antigenicity . 
Cell scrapings of breast cancers suspended in the RPMI culture media sho-
wed inferior IC results compared to IH of frozen tissue samples. For this 
reason we evaluated the influence of various media as well and found that 
preservation of cell morphology and inununoreactivity was best when suspen-
ded in either 1% BSA or Histocon. In agreement with Burton et al (12), we 
recommend immediate preparation (within I hour) of the cells to avoid deeli-
nation of antigenicity . Since I % BSA is easily contaminated by micro-orga-
nisms and fungi the use of th is medium is not recommended. 
By showing the influences of different preparatOly, fixation and storage 
methods we have emphasised the need of quality controlled, standardized 
methods of material processing and fixation of FNA material for IC staining 
especially with regard to nuelear antigens. Taking these technical problems in 
consideration, we find IC of FNA material areliabie teclmique for the asses-
sment of prognostic markers in breast carcinomas. 
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CHAPTER 5 
IMMUNOHISTOCHEMICAL DETERMINATION OF ANDROGEN 
RECEPTORS IN RELATION TO ESTROGEN AND PROGESTERONE 
RECEPTORS IN FEMALE BREAST CANCER. 
V.Kuenen-Boumeester, Th.H. v.d. Kwast, W.L.J. van Putten, C.C. Claassen, 
B.van Ooyen and S.C. Henzen-Logmans 
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5.1 SUMMARY 
The expression of estrogen (ER), progesterone (PR) and androgen (AR) 
receptors in female breast cancel' was investigated by illlmunohistochemistry on 
snap-frozen tissue specimens of a series of 100 breast cancers. For the detection 
of the AR we used a recently developed mouse monoclonal anti body specific for 
the N-terminal domain of the human AR. Expression of AR was compared with 
that of ER and PR as weil as with tumour grade and age. Of the breast cancers 
investigated, 76% were AR-positive. This high percentage corresponds weil 
with previous data on AR expression in breast cancel' detennined with ligand-
binding assays. In 53 % of the tumours AR, ER and PR were present, while 9% 
of the tumours were positivefor AR and negative for ER and PRo In 13 % of the 
tumours no ER, PR or AR expression was seen; these were all grade-Ill 
tumours. A positive correlation was found between age and ER expression, but 
no correlation was seen between age and PR or AR. Future studies should 
establish the prognostic value of the combination ER, PR and AR determinations 
on female breast cancel' with regard to biological behaviour and response rate 
to hormonal therapy. 
5.2 INTRODUCTION. 
The assessment of estrogen (ER) and progesterone (PR) receptors in breast 
cancers is used as a prognostic parameter and as an indicator of likely response 
to hormonal therapy (Thorpe, 1988). Less is known about the role and clinical 
significance of androgen receptors (AR) in the biological behaviour of breast 
cancer. A direct growth-inhibitory effect of androgens on 2 estrogen-dependent 
human breast cancel' cell lines has been demonstrated in vitro (Poulin et al, 
1988; Hackenberg et al, 1991), as weil as in vivo on carcinogen-induced breast 
tumours in a rat model (Dauvois et al, 1989). Lea et al (1989) showed that AR 
is the sex steroid hormone receptor most frequently found in both primary and 
metastatic human breast cancers. The expression of AR appears to be best 
preserved during the process ofmetastasis. Moreover, Teulings et al (1980) and 
Bryan et al (1984) found that data on AR expres sion added significantly to the 
prediction of survival and response to horlllonal therapy. 
Up to now, AR deterlllination has relied on ligand-binding assays. However, 
these methods are vulnerable due to the thermolability of the receptor, especially 
in combination with the action of proteolytic enzymes. Percentages of AR-
positive breast cancers reported in the literature vary from 35 % (Miller et al., 
1990) to 84% (Lea et al., 1989). Moreover, biochemical assays do not provide 
any information about cellular distribution. 
Recently, a Illonoclonal antibody (MAb) specific for the human AR has been 
developed. This MAb, designated F39.4, is specific for a unique epitope in the 
N-terminal domain of the hUlllan AR molecule (Zegers et al., 1991). Using 
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inllllunohistochemistry with this MAb, we visualized differences in percentage 
and intensity of AR expres sion in a series of JOO breast cancers. We also 
evaluated the clinico-pathological value of immunohistochemical AR 
determiuations by correlating expres sion of AR with ER, PR, histological 
grading and age. 
5.3 MATERlAL AND METHODS. 
Palie/If IlIaterial 
The patient material consisted of tissue samples from JOO primary breast 
carcinomas diagnosed in the period 1989-1991. The tumours were graded 
according to the Bioom and Richardson system with minor modifications as 
described by Page and Anderson (1987). Patients' age at the time of primary 
surgery was recorded. 
11111111111011 i s t oell e1lli suy . 
Representative tissue samples were snap-frozen in liquid nitrogen and stored at -
70°C until use. Cryostat sections, 4 I'm thiek were air-dried and subsequently 
fixed in formaline (4 %) diluted in phosphate buffered saline (PBS) for JO min. 
After rinsing in PBS, they were dehydrated in chilled methanol and acetone 
(-20°C). 
11111111111ostail1il1g for ER alld PRo Af ter rinsing in PBS, sections were pre-incu-
bated with normal goat serum (diluted 1: 10) for 15 min. Briefly, incubation with 
the primary MAb was perfonned overnight at 4°C, using kits commercially 
obtained from Abbott (Abbott Park, lL). The peroxidase anti-peroxidase 
complex method was used employing goat anti-rat immunoglobulin (30 min) as 
bridging antibody (Dakopatts, Copenhagen, Denmark). Af ter rinsing \Vith PBS, 
the reaction product was visualized using diamino-benzidine- H,O, as substrate. 
11111111/11ostaillil1g for AR. After rinsing in PBS, sections were pre-incubated 
consecutively with avidin (30 minutes), biotin (30 minutes) and normal rabbit 
serum (5 minutes) all used as blocking agents (Vector, Burlingame, CA). 
Between each blocking step sections were rinsed in PBS (2 x 5 min). Incubation 
with MAb F39.4 (ascites, diluted 1: JO ,000) was done for 24 hr at 4°C. Af ter 
rinsing with PBS, reactivity was visualized by a 30-min incubation \Vith 
biotinylated rabbit anti-mouse immunoglobulin diluted 1: JOO in PBS containing 
4 % normal human serum, followed by incubation with peroxidase-conjugated 
streptavidine (dilution 1:50, 30 minutes) (Dakopatts) as linking agent and 
diamino-benzidine-H,O, as substrate. For all antibodies, af ter a final wash, 
nuclear counterstaining was achieved by incubation in Mayer's haematoxylin for 
1 minute. Control sections consisted of known positive and negative specimens 
identified by ligand-binding assay. In addition, in one negative control section 
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the first-layer antibody was ehanged to PBS or non-immune aseites fluid. 
Qualllificatioll. 
The percentage of ER, PR and AR-positive tumour eells was ealculated by 
eounting the number of positive eells on a totalof 300 eells in 3 different areas 
of the tumour (PP-seore). The intensity of staining of eaeh eell was estimated 
visuallyon an arbitrary seale of 0 (no staining) to 4 (very intense staining). The 
average staining intensity (E-seore) was defined as 
'=4 E iP(i) with summation over i=O ...... , 4 
i=O 
in whieh P(i) = % stained tumour eells with intensity score i (Seheres et al, 
1988). 
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Figure 1. Corre/a/ion ofthe E-score mld PP-scorefor AR determilled ill 100 brenst carcinomas (see 
lexI). 
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For ER, PR and AR we demonstrated a close correlation (Spearman Rank 
correlation > 0.93) between the E-score and PP-score. In Figure I this 
correlation is shown for AR. Given the strong correlation between both 
measures, the one that is easiest to score (the PP-score) was used for further 
analysis. Arbitrarily, tumours were considered to be receptor-negative if less 
than 10% of tumour cells were stained. 
5.4 RESULTS 
AR positivity was found in 76% of the tumours (Tabie I). Nine percent of the 
tumours expressed AR as the only sex steroid receptor. Although most of these 
AR-positive tumours displayed a selective nuclear staining reaction of the 
tumour cells (Fig. 2), in some tumours some cytoplasmic staining of tumour 
cells was present. Similarly, ER and PR were selectively present in the nuclei. 
Stromal cells did not react with any ofthe antibodies employed. Most (82%) of 
the AR-positive tumours silOwed a high percentage (> 50%) of immunostained 
cells. Figure 3 shows the distributions of the PP-score of ER, PR and AR of all 
individual tumours tested. In 53 % of the tumours, all 3 sex steroid receptors 
were present. In 13 breast cancers none of the 3 receptors was detectable. The 
assoCÎation between AR, ER and PR status (Tabie I) is statistically highly 
significant. Afnong AR' tumours the majority was also ER and PR', whereas 
among AR + tumours the majority was ER+, PR +. This assoCÎation was also 
reflected in the mean PP-scores for ER and PR which were lower among AR' 
than among AR+ tumours (Fig.4). The level of AR positivity showed no further 
association with ER or PRo The mean PP-scores for ER and PR for tumours 
with a high AR level (PP-score AR > 50) were no different from the mean 
scores for tumours with a moderately positive AR level (10 < PP-score AR < 
50) (Fig.4). On average, the percentage of PR-positive tumour cells was lower 
than the percentage of AR+ or ER+ tumour cells. 
Table I. Expressioll of AR, ER alld PR ill breasl calleer 
ER+ PR+ 
AR + 53 
AR- 5 
ER+ PR-
12 
5 
ER- PR+ 
2 
ER- PR-
9 
13 
52 
Figure2. Direct visl/aliZa/ion ofheterogeneity of AR expressioll by illl11UUlostaillÎllg wUIi MAb F39. 4 
(Haemato.\ylin coltllferstaillillg); (a): immduelal breas! carcilloma wUb cribriform growl" paftert/. 
Selec/ive "uelear stailling of ,he majority ojtlllJlour cells. (b) lllfiltratillg duclal cafcil/oma o/flle 
brens'. Dark-stailled nuclei are immllllOlabeled for AR. 
'" PP-score 
100 
Figure 3. Distributioll of PP-scorefor ER, PR alld AR of 100 cases of brenst cafCÎI/Oma. 
AR EXPRESSION COMPARED WITH ER AND PR 
70 
• 
60 
· • , 50 
• 
• ,
, 
• 40 . 11 111 
30· 
20 
10 11 
0 
<10% 10-50% 
% AR positive tumour eells 
53 
Figure 4. Expressioll of AR cOll1pared witll that of ER alld PRo A1'erage percell/ages of ER+ (e) alld 
PR+ (iI; tUlllolir ceUs in breas! carcillomos with less (hall 10%, 10-50% alld over 50% of AR+ 
tumour ce/Is. 
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Correla/ion between grading and sex sleroid receplors. 
A clear correlation between grading and expression of the 3 different receptors 
was observed (Tabie Il). Grades land II showed a higher percentage of 
receptor-positive tumours than grade-III tumours. The 13 tumours in which none 
of the 3 receptors were detectable were all grade-Ill tumours. 
Table 11. Refatiollslzip of tull/OUf grade al/d sex steroid receptor expressioll 
Receptor status Tumor grade 
Grade I Grade II Grade III p-value' 
Total 18 46 36 
ER+ (%) 100 89 44 0.000 
PR+ (%) 67 76 39 0.002 
AR+ (%) 78 91 56 0.001 
JChi-square test 
Table 111. Age alld sleroid receptor profile 
Age 
p-value' 
Mean (SD) <50yr >50yr 
ER- 50 (10) 13 12 0.05 
+ 58 (12) 23 52 
PR- 55 (12) 13 26 0.66 
+ 57 (12) 23 38 
AR- 54 (12) 8 16 0.76 
+ 57 (12) 28 48 
IChi-square test 
Relationship of age with sex steroid receplors 
Table III expresses the relation between each receptor and agc. For all 3 
receptors, positivity occurred more frequently among older patients, but onIy 
for ER was the association statistically significant (p = 0.05). 
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5.5 DISCUSSION. 
The recent production of a MAb, designated F39.4 specific for the human AR 
enabled us to employ a simple immunohistochemical approach for direct light-
microscopic visualization of the AR in normal (Ruizeveld de Winter et al., 
1991) and neoplastic breast tissues (this study). We have previously shown that 
this MAb is higWy specific for human AR as it shows no cross-reactivity with 
ER, PR or glucocorticoid receptor (Zegers et al., 1991). Immunoreactivity of 
various human tissues with this antibody was generally consistent with earlier 
biochemical and autoradiographical data (Ruizeveld de Winter et al., 1991). 
By analogy with the results obtained with immunostaining for ER and PR, we 
found that AR is predominantly located in the nuclei of the immunopositive 
cells. As in earlier studies with ligand-binding techniques, we found in general 
a good correlation between AR, ER and PR expression, i.e. most AR-positive 
tumours also contained ER+ and PR+ tumour cells. However, the percentage of 
PR + tumour cells within a given tumour on average was lower than that of ER 
or AR (Fig. 4). This latter observation stands in contrast to the findings of Lea 
et al. (1989) who found in breast cancel' cytosol preparations alowel' 
concentration of AR than of PR or ER. In their study, a labelled ligand-binding 
assay was used and therefore this discrepancy with our results could be due to 
the difference in methodology. In agreement with the findings of Lea et al. 
(1989) and those of Miller et al. (1985), we observed that a high percentage of 
breast carcinomas contained AR+ tumour cells (76%); 9% contained AR as their 
sole sex steroid receptor. 
Clinical data have shown the benefits of androgen therapy in metastatic breast 
cancel' (Manni et al., 1981; Tormey et al., 1983; Ingle et al., 1988). Teulings 
et al. (1980) also described a favourable response to progestin in a group of 
estrogen-responsive breast cancers and demonstrated that within this group the 
actual AR levels determined the response. Bryan et al (1984) as weil as Langer 
et al (1990) confinned that AR data add significantly to the prediction of 
slll'vival and response to endocrine therapy. As progestin as weil as progesterone 
can be metabolized into an androgen, these steroids may exert their effect by 
interaction with AR. This mechanism of AR-mediated inhibition of tumour 
growth mayalso explain the beneficial effect of high doses of progestin 
observed in PRo breast tumours (Teulings et al., 1980). In our study, the AR+ 
PR' subset of breast carcinomas comprised 21 % of the cases. Distinction of this 
AR +PR' subgroup of breast cancers might lead to a more specific type of 
endocrine therapy, including administration of androgens. 
The in vitro findings of Poulin et al (1988), and Hackenberg et al (1991) on the 
hUll1an breast-cancer cell lines ZR-75-1 and MFM-233, respectively, support 
the notion of an AR-ll1ediated growth inhibition of human breast cancer. In both 
celllines the anti-proliferative effect of androgens could be cOll1pletely reversed 
by the anti-androgen hydroxy-flutamide. Similarly, an in vivo inhibitory effect 
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of androgens on DMBA-induced mammary tumour growth in the rat was noted. 
This anti-proliferative effect of androgens could also be completely prevented 
by simultaneous treatment with hydroxy-flutamide (Dauvois et al., 1989). In 
contrast, addition of high doses (1 I'M) of androgens induces a growth 
stimulation in the human breast carcinoma cell lines MCF-7 and EFM-19 
(Hackenberg et al., 1988). To add to the complexity of the picture, it was also 
found that these high doses of androgen led to an increase in PR content and 
that in MCF-7 cells the androgen dihydrotestosterone was rapidly converted to 
androstane-3Jl, 17Jl-diol, which may exert an estrogenic effect in this cell line 
(Zava and McGuire, 1978). 
Not only do androgens act by modulating tumour growth, but also the 
production of peptidases by benign and malignant breast lesions is dependent on 
androgens. Thus, gross cystic disease fluid protein-15 and 24 production by 
human breast cancel' cells is stimulated by androgens (Dauvois et al., 1990; 
Simard et al., 1990). 
Earlier studies demonstrated that the presence of ER and PR is related to 
histological grading of breast cancers (Thorpe 1988). Indeed, in our series an 
opposite relationship between tumour grade and expression of ER and PR was 
present. The same treud also holds true for AR expression. Moreover , 13 of the 
100 breast carcinomas were negative for all 3 sex steroid receptors, all of which 
represented grade-III carcinomas. On the other hand, about half of the grade-III 
breast cancers sIlOwed expressioll of one or more receptors. Follow-up studies 
should establish whether determination of the 3 sex steroid receptors is a better 
independent predictor of survival from breast cancer than grading. 
AltllOUgh with increasing age the percentage of ER + breast tumours was 
increased (p=0.05, Table III) this relationship was not present for PR or AR. 
This finding is in agreement \Vith the data from Lea et al. (1989), Bryan et al. 
(1984) and Miller et al. (1985). 
In conclusion, the possibility of a simple immunohistochemical detection of AR, 
ER and PR in breast cancers can now be used to distinguish betweell subsets of 
breast cancers which may respolld to estrogells or alldrogens in a specific way. 
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6.1 ABSTRACT 
To analyze the clinical significance of the presence of androgen receptors (AR) 
in breast carcinomas, clinical and histological parameters of 153 primary breast 
carcinomas (median follow-up 46 months) were examined. Estrogen (ER) and 
progesterone receptor (PR) levels were determined in cytosol preparations using 
enzyme immunoassays and in cryostat sections by inl1llunohistochemistry. AR 
and Ki-67 levels were only determined immunohistochemically. Data were 
analyzed by uni- and muItivariate modeis. 94/153 (61 %) breast carcinom3s were 
ER + PR + AR +, while 14 cases were only positive for AR. 
All steroid receptor negative cases (n = 17) were grade III cancers and 14 (76 %) 
of these cases demonstrated high Ki-67 values suggestive of a more aggressive 
behaviour. Strikingly, 14 ductal carcinomas negative for ER and PR were 
positive for AR. In univariate analysis, AR as weil as ER, tumour size, Iymph 
node status, grade and Ki-67 proved to be significant prognostic factors for 
disease-free survival (DFS). Multivariate analysis, however, silOwed Iymph node 
status, tumour size and ER status to be the only independent prognostic factors 
for DFS within this model. We conclude that simple histological and cell-
biological parameters, including AR, can be used to select high- and low-risk 
patients at the tin,e of primary surgery and can provide valuable information on 
treatment options. 
6.2 INTRODUCTION 
The importance of the histological subclassification of breast cancel' as one of 
the indicators for tumour aggressiveness is weil recognized. Histological 
subtypes, such as tubular, cribriform and colloid cancers, are known to have a 
good prognosis, while not otherwise specified (NOS) ductal carcinomas have a 
relatively pOOl' prognosis; the lobular, medullary and mixed carcinomas are 
considered to represent an intermediate prognostic group (1-5). Other tumour 
characteristics, such as Iymph node status and histological grading, are 
considered to be of major importance (1,2,5-9). The prognostic impact of 
additional parameters, such as proliferative activity (10-12) and the expression 
of estrogen (ER) and progesterone receptors (PR) is also weil established 
(13,14). A relationship between subtypes of breast cancel' and proliferative 
activity has been demonstrated in both histological (12,15) and cytological 
material (15). 
The clinical significance and functional role of androgen receptor (AR) 
expression in breast cancel' is less weil defincd. In a previous study (16) on 
human breast cancel', we found a close relationship between AR, ER and PR 
expression. AR was detectable in 76% of the 100 cases of breast cancel' 
investigated. Nine percent of the tumours expressed AR as the only sex steraid 
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receptor. As various studies (17,18) have reported that the combiued use of 
androgen and anti-estrogen therapy has therapeutic advantages over anti-estrogen 
treatment alone, AR determination may give additional information regarding 
the response to different endocrine treatment modalities. 
In tbis study we report on the prognostic impact of the aforementioned tumour 
characteristics, with special emphasis on the relationship between AR and these 
factors. 
Using these parameters, we perfonned uni- and multivariate analyses. In 
addition, we correlated ER and PR detected immunohistochemically with ER 
and PR levels measured by a biochemicalmethod based on the enzymeimmuno 
assay (EIA). 
6.3 PATIENTS, MATERlALS AND METHODS 
Patients. 
This study was performed on a group of 153 patients (mean age 55 years, range 
29-88 years) with primary breast cancer who underwent either breast conserving 
surgery (n=71) or modified mastectomy (n=82) with axillary lymph node 
dissection from 1988 to 1991 in the Dr Daniel den Hoed Cancer Centre (median 
follow-up 46 months, range 12-73 months). Patients' age and menopausal status 
were recorded at the time of primary surgery. The tumoUl's were graded 
according to Bloom and Richardson with minor modifications as described by 
Elston in Page and Anderson (19). Histologieal typing was performed following 
the WHO classification (20), modified according to Page (19). Only patients 
without signs of distant metastasis at the time of surgery, with lmown 
immunohistochemieally detennined ER, PR and AR status and known follow-up 
were included in th is study. All patients were routinely examined every 3-6 
months during the first 5 years. In the follow-up period, 46 patients (30%) 
showed evidence of recurrent disease, and 25 of these women died. 3 patients 
died without recurrent disease. 
Methods 
Biochelllimy. In 133/153 cases, material was also available for cytosolic ER and 
PR assays. As described previously (14), tumour tissue (0.4-0.8 g) was 
pulverised and homogenised as recommended by the EORTC for processing 
breast tumour tissue for cytosolic ER and PR dcterminations. The homogenate 
was centrifuged for 30 min at 100,000 g at 4 oe, and the supernatant fraction 
(cytosolic extract) was used for ER and PR determination by enzyme 
immunoassays (ER-EIA and POR-EIA kits, Abbott, Chieago, Illinois)) (cut-off 
values 10 fmol/mg protein). 
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Immlll/oilislocilemislly. The immunohistochemical methods used have been 
previously described (15,16). In short, representative tissue samples were snap-
frozen in liquid nitragen and stored at -70°C until use. Praliferative activity was 
assessed with MAb Ki-67 (DAKO, Glostrup, Demnark). Cryostat sections, 4f'm 
thick, were air-dried and fixed in acetone for 10 min, aftel' which the indirect 
immunoperoxidase technique was used for visualizing Ki-67. For 
immunostaining of ER, PR and AR the cryostat sections were fixed with 
formalin (4%) diluted in phosphate-buffered saline (PBS). Incubation was 
performed with the ERICA or PRICA kits for ER and PR, respectively 
(Abbott). For inllnunostaining of AR, tbe MAb F39.3 was used, specif1c to a 
unique epitope in the N-terminal domain of the human AR molecule (21). 
Specific binding of ER and PR was visualised using the peroxidase-
antiperoxidase (PAP) technique; for AR the s-ABC (streptavidin-biotin-enzyme 
complex) technique was applied. All immunostained sections were 
counterstained with Mayer' s haematoxylin for 1 min. Con trol sections consisted 
of known positive and negative specimens identified by ligand-binding assay. In 
addition, for negative control sections, the primary antibody was replaced with 
PBS or non-immune ascites fluid. 
QlIal/lifiCaliol/. The percentage of ER-, PR- and AR-positive tnmour cells was 
calculated by counting the number of positive cells in a total of 300 cells in 
three different areas of the tnmour (16). A staining percentage of less than 10 
was regarded as negative. 
The Ki-67 score was assessed by counting 300 cells in the areas with the highest 
proliferative activity, as described previously (15). Arbitrarily, tnmours with a 
Ki-67 score equal to or over 20% were defined as tnmours of high proliferative 
activity. In 5 cases, no Ki-67 could be assessed, due to inadequate staining 
results (n=4) and loss of material (n= I). 
Slalistics. Spearman rank correlations (r,) were used to stndy assocIatIons 
between continuous variables. The associations between continuous and grouped 
variables were tested using the Wilcoxon rank sum or the Kruskal-Wallis tests 
and the associated trend test, when appropriate. When patients died of unknown 
causes, they counted as failures for disease free survival (DFS) at time of death 
(n=3). The Cox proportional hazards model was applied for both univariate and 
mllltivariate analyses, using the associated likelihood ratio test to test for 
differences. Cox regres sion analyses are sununarized in Table 4 by the relative 
relapse rates. 
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Relapse-free survival probabilities were calculated by the actuarial method of 
Kaplan and Meier. The log rank test for trend was used for curves with three 
ordered groups. For all tests we considered a two sided p-value of less than 5%, 
as significant. Because of the relatively short follow-up period of the patients 
and, as aresuIt the low number of events in overall survival, we chose to focus 
only on DFS. 
6.4 RESULTS 
Patielll al/d tumour cilaracteristics. 
Patient and tumour characteristics are summarized in Table I. The histological 
subtypes included 114 ductal, 14 lobular, five colloid, two tubular, one 
cribriform, 14 mixed, two medullary carcinomas and one metaplastic carcinoma. 
Of the premenopausal women with positive lymph nodes (n=36), 27 received 
adjuvant chemotherapy, one hormonal therapy and eight received no adjuvant 
therapy. Postmenopausal women with positive lymph nodes (n=38) received 
adjuvant hormonal therapy in 10 cases, adjuvant chemotherapy in 13 cases, 
while 15 received neither chemo· nor hormonal therapy. 
Correlation betweel/ ER al/d PR data assessed immul/ohistocilemically al/d 
cytosolic ER alld PR levels measured witil EIA. 
Immunohistochemically detectable nuclear ER and PR were present in variabIe 
percentages of the tumour celIs, but not in stromal cells. 
The Spearman rank correlation between data obtained immunohistochemically 
and data obtained by EIA was r, = 0.66 (p<O.OOOI) for ER, and r, = 0.74 
(p<O.OOOI) for PRo When dichotomised, a discordance was observed in 11 
cases for ER and in 20 cases for PRo 
Associatioll betweell expressiol/ of til ree steroid receptors alld Ki-67 score. 
The relationship bet ween the immunohistochemical expression of the three 
examined steroid receptors is shown in Table 2. In 94 cases (61 %), expression 
of all three receptors was observed. Interestingly, in 14 cases (9%) only AR 
expression was found. 
An inverse relationship between AR, ER and PR expression and the Ki-67 score 
was demonstrated; a high Ki-67 score was significantly (p < 0.01) associated 
with low receptor values (data not shown). 
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Table 1 Pa/ient alld llImoflr cJwracteristics 
n % 
Patients 153 
premenopausaI 70 46 
postmenopausal 83 54 
Tumour 
Itistology 
T Tl 77 50 
T2 55 36 
T3 12 8 
T4 4 3 
Tx 5 3 
N No 78 51 
NI-3 49 32 
N>3 25 16 
unknown 1 
type ductal 114 75 
lohular 14 9 
others 25 16 
Grade 20 13 
II 79 52 
III 54 35 
biochemisfry 
ER <10 31 20 
;,,10 102 67 
unknown 20 13 
PR <10 45 29 
;,,10 88 58 
unknown 20 13 
lmmulloltis(ochemisfry 
ER <10 32 21 
;,,10 121 79 
PR <10 54 35 
;,,10 99 65 
AR <10 25 16 
;,,10 128 84 
Ki-67 <20 97 63 
~20 51 33 
unknown 5 3 
AR, androgen receptors; ER, estrogen receptors; PR, proges!erone receptors. 
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Table 2. Relatiol/ship be/ween tlle itlllllllllOhistochemical expressioll of fhe (!tree sleroiel receptors 
Positivity for AR 
< 10 (%) > ~ 10 (%) 
ER- PR-(1I~31) 17 (11) 14 (9) 
ER+ PR-(1I~23) 4 (3) 19 (12) 
ER- PR +(II~ 1) 0(0) 1 (0.7) 
ER+ PR+(1I~98) 4 (3) 94 (61) 
Total (II~ 153) 25 (16) 128 (84) 
Table3. Correlatiollhetweell sleroid receptor expressioJl. Ki-67 alld Izistological typilig alld gradillg. 
Histology 11 ER PR AR Ki-67 "'20 
(%) (%) (%) (%) 
Ductal NOS 114 75 62 84 38 
Lobular 14 100 71 92 14 
Mixed 14 85 64 78 28 
Special types 
colloid 5 100 100 100 0 
tubular 2 100 100 100 0 
cribrifonn 100 100 100 0 
Others 
medullary 2 0 0 0 100 
metaplastic 0 0 0 0 
Grade 
I 20 100 75 95 0 
II 79 75 63 75 15 
III 54 79 39 63 66 
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Correlatioll betweell steroid receptor expressioll, Ki-67 score alld histological 
typilig alld grading. 
A variabie steroid receptor expres sion and Ki-67 score was found in the group 
of NOS ductal carcinomas (Tabie 3). Of the 17 receptor-negative tumours, 14 
were NOS ductal carcinomas. Strikingly, 13 of these 14 cases expressed high 
(;:0, 20) Ki-67 values. In addition, the 14 cases negative for ER and PR and 
positive for AR were all NOS ductal carcinomas. The colloid, cribriform and 
tubular carcinomas combined ER, PR and AR expression with low ( < 20) Ki-67 
values (Tabie 3). Figure 1 shows this variation in staining for a colloid 
carcinoma. 
Figure 1. Comparisoll of Ki-67 olld alldrogell receptor (AR) ÎlIIllIlillOstaillillg offrozen sectiolIs of 
(he same callairl breas! carcilloma (magnificat/Dil 4Gr). (a) OJ/ly feil' tumour ceUs (darker nuclei) 
show pos/live stafllillg of Ki-67. (b) Posith'e IIflclear Staillillg (darker Jluclei) for AR is preselll til file 
majority of tlllllour cel/s. 
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The mixed (n= 14) and lobular (n= 14) type carcinomas formed an intermediate 
graup (Tabie 3): only one mixed type carcinoma lacked all three receptors and 
2/14 lobular (14%) and 4/14 mixed (29%) carcinomas expressed ;0,20% Ki-67 
positive cells. In contrast the medullary (n =2) carcinomas combined high Ki-67 
scores with absence of steraid receptor expression, and the metaplastic 
carcinoma combined receptor negativity with low Ki-67 score (tabie 3). 
The correlation between immunohistochemically detected steraid receptor 
expression and grade is presented in Table 3. Grade land Il carcinomas showed 
a higher percentage of receptor-positive cases in comparison to grade III 
carcinomas. Moreover, all receptor-negative cases (n= 17) were grade III 
cancers, in 14 cases characterised by a high percentage of Ki-67 positive cells. 
The 54 grade UI tumours consisted predominantly of NOS ductal carcillomas 
(n=49). 
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Table 4. COX Univariate- and Multivariate Analysis in 147" Primary Breast Cancer Patients 
---------
---------------------------------- ----------------
Univariate Multivariate Onitial model) Multivariate (final model) 
variabie HRb 95% Cl' P HR 95% Cl P HR 95% Cl P 
----------------------------------------------------------------------------
pT' 2.08 1.44 - 2.99 0.000 1.79 1.19-2.69 
nodal status 
1-3' 1.37 0.68 - 2.76 1.46 0.69-3.11 
>3 3.36 1.63 - 6.91 0.004 2.64 1.16-5.98 
lH-ER' 0.43 0.23 - 0.81 0.008 0.40 0.14 - 1.14 
IH-PR' 0.61 0.34 - 1.08 0.091 1.85 0.71 - 4.80 
lH-AR' 0.50 0.25 - 0.98 0.043 0.65 0.27 - 1.57 
BR' 1.79 1.12-2.86 0.014 1.20 0.86 - 2.19 
KI-67 1.79 1.00 - 3.22 0.052 1.05 0.51 - 2.17 
a5 Patients tumor-size unknown and of 1 patient nodal status unknown. 
b Relative Hazard Rate 
, Confidence Interval 
'Test for trend. 
, T ested vs node-negative. 
, Dichotomized. 
0.005 1.69 1.14 - 2.51 0.009 
1.53 0.75 - 3.09 
0.067 2.62 1.20 - 5.71 0.052 
0.087 0.39 0.21 - 0.74 0.004 
0.205 
0.337 
0.544 
0.902 
'" 00 
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Correlatiolls betweell steroid receptors, Ki-67 alld clillical parameters. 
No significant association between immunohistochemically detected steroid 
receptor expression and Iymph node status was obselved. A significant 
correlation was seen for ER and age (r,=0.28, p < .01); an inverse relationship 
for tumour size and PR (Kruskal-Wallis associated trend-test p= 0.03) was 
seen. A borderline significant inverse relationship was found for Ki-67 score 
and age (1',=-0.16, p=0.05) and a significant rank correlation (r, =0.21, 
p=O.OI) for Ki-67 score and Iymph node status. 
DFS accordillg to variolIs parameters 
At 60 months, the DFS of the 153 patients was 64.7% with 16 patients at risk. 
The results of univariate analysis (TabIe 4) indicated an increased risk of relapse 
for patients with larger tumours, with high grade tumours (Figure 2a) and with 
more than three lymph nodes affected (Figure 2b). Similar findings were 
observed when patients were stratified according to ER positivity (P=0.008), 
AR expres sion (P=0.043) and Ki-67 score (P=0.052). Not surprisingly, EIA-
ER showed a similar correlation with DFS as did immunohistochemically 
detected ER (Figure 3). 
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Figure 3. Disease-free survival curve for estrogen reeep/ors (ER) accordillg fo the method of 
de/ectloll. 
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Figure 4 gives an indication of the DFS according to the various 
immunohistochemically determined receptor combinations. For DFS, the 
patients with ER + ,PR + ,AR + tumours had the best prognosis, and the group 
with a combination of negative AR, ER and PR had the worst prognosis (p = 
0.026), but the number ofpatients was low (n=17). 
The results of the Cox regression analysis are shown in Table 4. Relative hazard 
rates (HR), the 95 % confidence intervals (95 % Cl) and p values are given for 
both the univariate and multivariate analyses. The results of both the initial and 
final multivariate models are shown. The addition of adjuvant therapy, which 
was not statistically sigrtificant in the urtivariate analysis, had no influence on 
the estimations of the irtitial model. It appeared that tu.maur size and nodal status 
were the major prognostic factors, with ER stattls showing an additional 
prognostic value. Given these factors, tlle others silOwed no statistically 
significant assaciations in the final model. Estimations of the relative HR of 
tumour size (HR 1.70, 95% Cl 1,15-2.51) and immunohistochemically detected 
ER (HR.36, 95% Cl 0.19-0.69) were not influenced by adding adjuvant therapy 
as an indicator variabie ta the final model, as campared to Table 4. 
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Figure 4. Disease-free survival curves for patients with tumours of different 
estrogenlprogesteronlandrogcn receptor (ER/PR/AR) phenotypes. Patients with ER-, PR-, AR-
tumours had Ihe worst prognosis (p=O.026). Numbers in parentheses show failuresftolal amount of 
patients in each group. 
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6.5 DISCUSSION 
In recent years, the EIA has become an alternative method to the conventional 
dextran-coated charcoal (DCC) assay. Like others (22,23) we found good 
correlation (p < 0.0001) between values obtained by EIA and those using 
immunohistochemistry. In addition, the prognostic impact of ERiPR detected by 
either method was similar (Figure 3). The observed discrepancies between EIA 
and immunohistochemical determination may be partly related to variations in 
the proportion of tumour tissue in the specimens examined, and partly to the 
presence of receptor-positive benign epithelium in EIA samples, resulting in 
false positive ER and PR values. Loss of antigenicity due to material processing, 
especially in the case of the lalown labiIe PR, may give an additional 
explanation for the discordances. No biochemical data for AR were available for 
this material, but Ruizeveld and associates (24) observed that immunoreactivity 
with this antibody was generally consistent with earlier biochemical and 
autoradiographical data. As primary tumours are of increasingly smaller size at 
primary surgery, due to breast cancer screening programmes , immunohistoche-
mical measurements of steroid expression may, in the future, become an 
acceptable alternative to the binding assay, particularly as monoclonal anti-
steroid receptor antibodies for use on paraffin sections have become available. 
The inverse relationship of Ki-67 positivity with ER, PR and AR expres sion was 
similar to the results obtained in other studies for ER and PR (10,25,26). 
However, Wintzer and associates (27) found no correlation between Ki-67 and 
ER status and an inverse relationship between Ki-67 and PR; Gasparini and 
associates (28) made the opposite observation. These controversies may partly 
be explained by differences in the assays used and partly by differences in cut-
off levels. Isola (29) correlated AR with proliferation as determined by the S-
phase fraction, but found only a weak inverse association. 
The relationship between pure histological parameters, such as typing, grading 
and the biological behaviour of breast carcinomas, has already been emphasized 
(1-5). As the aggressiveness of a tumour mayalso be reflected by the presence 
or absence of a number of other tumour characteristics, it seemed logical to 
relate the histological parameters to these markers. In agreement with an earlier 
study (15) we found that the Ki-67 defined proliferation index was related to 
particular types of breast cancel' (see Table 3), and that most cases with high Ki-
67 positivity were found in the group of NOS ductal carcinomas. No significant 
correlation was demonstrated between either Ki-67 expression or steroid 
receptor expression and grade. Yet all steroid receptor negative tumours 
(11=17), that is AR-, ER-, PR-, appeared to be grade III tumours. Moreover, 
14 cases of this group appeared to be NOS ductal carcinomas and 13 
demonstrated high (;0, 20) Ki-67 activity. These findings emphasize the view that 
lack of all three steroid receptors, combined with high proliferative activity and 
high grading, are associated with a more aggressive tumour behaviour. This is 
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substantiated by the DFS data (fig 4). In contrast, and in Jine with pubJished 
results (1-5, 25), we found that the colloid, tubular and cribriform tumours 
combined steroid receptor positivity, including AR, with low Ki-67 values and 
low grading (Tabie 3). In addition, consistent with the view that the group of 
mixed and lobular carcinomas represent a group of tumours with intermediate 
prognosis, we observed that only one of 28 mixed and lobular type carcinomas 
lacked all 3 steroid receptors (tabie 3) and only six of 28 contained ;;e 20% Ki-
67 positive tumour cells. The same relationship was found with respect to 
grading: only 2 of 28 mixed and lobular type carcinomas were grade III 
tumours. 
TeuJings and associates (30) stated that the positive response to treatment with 
high-dose progestin (megestrol acetate) in a group of patients with metastatic 
breast cancers was determined by the AR level. Moreover, Hackenberg and 
colleagues (31) demonstrated in vitro that the progestin medroxyprogesterone 
acetate inhibits proJiferation of a ER- and PR-negative cancel' cell Jine via AR. 
Therefore, AR positivity may have additional therapeutic consequences, 
particularly in the group of carcinomas with high proliferative activity and with 
the presence of only AR sex steroid receptor, as was observed for 14 NOS 
ductal carcinomas. Unfortunately, in our series, the number of patients receiving 
honnonal treatment for advanced disease was too small to study this 
re1ationship. 
The prognostic impact of tumour size, lymph node status, ER, AR, Ki-67 and 
grade in ullivariate analysis, emphasises the importance of these parameters. In 
the multivariate analysis, we confirmed (6,26) that Iymph node status, tumour 
size and ER expression were the only independent prognostic factors and that 
neither AR, nor Ki-67 offered additional discriminating abilities. 
In contrast to the large studies of Dixon and associates (2) and Pereira and 
associates (5), our study included a relatively small group of 34 patients with 
non-ductal carcinomas. Consequently, a reJiable statistical analysis of these 
subsets of breast cancers was not possible. Nevertheless, we feel that our results 
emphasise the importance of histological typing and grading of individual 
tumours. Moreover, they indicate, that these histological parameters in 
combination with a few common cell biological parameters, including AR, may 
help in the initial selection of high- and low-risk patients. Fm'ther refinement 
in choice of treatment for each individual patient may then be reaJised by using 
these parameters. 
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CHAPTER 7 
TP53 ALTERATIONS IN PHYLLODES TUMOURS 
Vibeke Kuenen-Boumeester MD, Sonja C. Henzen-Logmans MD PhD, 
Mieke M. Timmermans BSc, Iris L. van Staveren BSc, Albertus N. van Geel 
MD PhD and Els M.J.J. Berns PhD. 
C%U red illustrations in this chapter 
have been p/aced at page 97. 
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76 
7.1 ABSTRACT 
The histological characteristics of phyllodes tumours of the breast are often not 
related to their clinical outcome. Additional studies are performed to investigate 
the possible relation of cell biological parameters to the biological behaviour of 
these tumours. We report a case with a histologically malignant phyllodes 
tumour with known clinical follow-up. Expression of TP53, Ki-67 and TP53 
regulated proteins in the primary and in the recurrent and metastatic tumours as 
weil as in adjacent benign breast tissue were studied using immunohistochemi-
cal and molecular biological techniques. A high expres sion of Ki-67 (30%) and 
TP53 (90 %) was found both in the primary tumour and in the recurrent tumour 
sample, moreover in all tumour samples the same TP53 gene mutation, 
Arg273Cys, was detected. No mutation was found in adjacent normal breast 
tissue indicating that it was an acquired mutation. The case presented here 
illustrates that detection of TP53 gene alterations may offer new prognostic 
information in phyllodes tumours of the breast. 
7.2INTRODUCTION 
Phyllodes tumours of the breast are characterized by leaflike projections of 
hypercellular stroma with cleft-like spaces lined by ductal epithelium. It is a rare 
fibroepithelial neoplasm of the breast that accounts for < 1 % of the breast 
tumours in females. About 25 % of phyllodes tumours are considered to be 
histologically malignant, thus resembling soft tissue sarcomas (I). Unfortunately 
the histological characteristics are usually not related to the clinical outcome 
(6,12,18,22). Studies on modern prognostic factors in phyllodes tumOllfS may 
reveal their reiation to the biological behaviour of these tumours. 
TP53, also known as P53, and MDM2 gene alterations have been described in 
numerous tumours including breast cancer and sarcomas. The human MDM2 
gene, located on chromosome 12q13-14, has been found to be amplified and/or 
overexpressed in 15-30% of sarcomas (7, 13) and amplified in 4-10% of human 
breast tumours (9,17). The MDM2 protein binds directiy to the TP53 proteill 
and is able to block TP53 mediated transactivation (4). TP53, located on the 
short arm of chromosome 17, has been implicated in the regulation of normal 
cell growth and division, DNA repair and apoptosis. This tumour suppressor 
gene is found to be freqllentiy (14-52%) altered in human primary breast 
carcinomas (3,8) and in about 25% of sarcomas (7,21). In general, mutations 
give rise to a conformationally altered protein which, due to a prolonged half-
live, is stably expressed at high levels. Both MDM2 overexpression and TP53 
mutations are alternative mechanisms of TP53 dysfunction. Neither TP53 gene 
alterations nor MDM2 amplificationfoverexpression in phyllodes tumours of the 
breast have, as yet, been studied. 
In our ongoing studies on modern prognostic factors in phyllodes tumours four 
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cases out of 20 cases studied (one malignant, two borderline and one benign) 
showed an overexpression of TP53. In only one of these four cases, i.e. the 
histologically malignant phyllodes tumour, a TP53 gene mutation in the primary 
tumour, was found. This patient developed alocal recurrence and two distant 
metastases at 12, 15 and 21 months respectively after adjuvant radio- and 
chemotherapy of which frozen material was avaiIable for immunohistochemical 
and molecular biological analysis. The assessment of TP53 gene alterations not 
only in the primary, but also in the recurrent and metastatic tumour tissue of 
this particular patient is presented in this paper. In addition we analyzed TP53 
regulated proteins inciuding P21 WAF/SDIICIPI, MDM2 and the apoptosis related 
proteins BAX, and BCL2 in all tumour samples. 
7.3 CLINICAL HISTORY 
A 53 year old woman underwent a radical excision of a tumour in the left breast 
in May 1993. Histological examination showed a malignant phyllodes tumour 
with invasion of the deep surgical margin at the chest wall. Postoperative 
radiotherapy was given. After 12 months salvage mastectomy and chestwall 
resection was performed for local recurrence, and tlrree months thereafter lung 
metastases were observed. Six courses of chemotherapy (Adriamycinl 
Ifosfamide) were given, followed by surgical removal of the lung metastases and 
another two courses of chemotherapy. In March 1995 phase I chemotherapy was 
given for subcutaneous chestwall metastases without effect, folio wed by 
resection and interstitial radiotherapy with an Irl92 implant. In July 1995 one of 
the large subcutaneous metastases next to the contralateral breast was removed. 
The patient died in August 1995, no postmortem examination was performed. 
7.4 MATERlAL AND METHODS 
Histological features of the tumour were determined following standard criteria, 
modified according to Moffat et al 1995 (18) (Tabie 1). Frazen tissue samples 
of the primary tumour (I), its local recurrenee (II) together with frozen tissue 
samples of benign breast material (I1I) and of two metastases (IV = lung, 
V = chestwall) of the same patient were used for this study. 
lll/II/I/lloh is toch eli/ i st Iy 
Immunostaining was calTied out on cryostat sections, 4 I'm, which were air-
dried, fixed in acetone (in case of Ki-67, P53, BCL2 and BAX staining) or in 
formaldehyde 4% (in case of MDM2 and P21 staining) for 10 min. Monocional 
antibodies used: Ki-67 (Ki-67 DAKO, Glostrup, Denmark; working dilution 
1110); P53 (1801, Oncoscience, working dilution 11500 and DO-I, Santa Cruz, 
Santa Cruz, Cal, USA, working dilution 11100», MDM2 (Ab-I, Calbioch, 
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Cambridge MA, USA, working dilution 1140), P21 (2G 12, Pharmingen, San 
Diego, Ca, USA, working dilution 1120), BCL2 (124, Dako, Glostrup, 
Denmark, dilution 11100) and BAX (4Fll, Immunotech/Coulter, Westbrook, 
Maine, USA; ready for use). The APAAP technique was applied for visualising 
the antibody , as described previously (23) A colon cancer (Ki-67 and P53), 
Iymphnode (BAX and BCL2) , rhabdomyosarcoma (MDM2) and P21 positive 
mamrnary ceU line were used as positive controls. In addition, as a negative 
control, the primary antibody was replaced with PBS or non-immune ascites 
fluid. 
QlIantifiea/ion 
The percentages of P53, MDM2, P21, BAX and BCL2 positive (tumour) ceUs 
were estimated, by two independent observers (VKB and SHL) , by counting the 
number of positive ceUs in a total of 300 ceUs in three different areas of the 
tumour. The Ki-67 score was assessed by counting 300 ceUs in the areas with 
the highest proliferative activity, as described previously (16). 
DNA ex/me/ion, PCR-SSCP and seqllencing analysis. 
The frozen (tumour) samples were pulverized and homogenized in phosphate 
buffer according to the EORTC procedure (EORTC Breast Cancer Corporative 
Group, 1980). High molecular weight chromosomal DNA was isolated and 
exons 4 through 9 of the TP53 gene were analyzed using polymerase chain 
reaction and single-strand conformation polymorphism analysis (PCR-SSCP), 
as described previously (3). The breast cancer ceU-lines SKBR-3 (mutated at 
codon 175 in exon 5), T47-D (mutated at codon 194 in exon 6), EVSA-T 
(mutated at codon 241 in exon 7) and the colon celHine HT-29 (mutated at 
codon 273 in exon 8) were used as positive controls, whereas ZR75-1 was used 
as a negative control. Samples showing an altered migration pattern were 
analyzed again, using an independent PCR product, and subsequently 
sequenced. Sequencing was performed using the "Ampli Cyc1e"" sequencing" kit 
from Perklin Elmer (Branchburg, New Jersey, USA) and 5-prime 33p end-
labeUed primers. The DNA sequence was detennined by electrophoresis of the 
terminated products on a 6% denaturing polyacrylamide gel, containing 8M 
urea, foUowed by autoradiography. 
7.5 RESULTS 
The primary tumour was characterized as malignant (Tabie 1), due to high 
ceUularity of the stroma with nuc1ear polymorphism, stromal overgrowth and 
high mitotic rate (> 10 mitoses per 10 high power field (HPF)), shown in figure 
IA. The samples of the loc al recurrence and the metastases showed similar 
features. 
Table 1. Histological features 
stromal characteristics 
stromat cellularity 
nuclear polymorphism 
stromal overgrowlh 
tumour margin invasive 
mitosesl 10 Hpp2 
necrosis 
heterologousstromal elements3 
1 .' "I/ot applicable 11 
Primary tumour(l) 
+++ 
+++ 
+++ 
> 10% 
> la 
2 " mUl/ber of mitoses per 10 HPF = high power field 
J: malignolll bOlle alld carlilage 
IJ/IIlllIl/ohislochelllislly 
recurrence (II) 
+++ 
+++ 
na l 
na l 
> la 
+/-
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The staining patterns of the primary tumour (sample I), its local recurrence 
(sample II), benign breast tissue (sample III) and lung and chestwall metasta-
ses (samples IV and V respectively) with regard to different antibodies are 
summarized in Table 2. Ki-67 expression was absent in normal tissue, similar 
for both the primary (I) and the recurrent ttlmour (II) (30% versus 30%), but 
higher in the metastases ( 60%-50%). A heterogenous staining pattern was 
observed for P53 in the primary tumour, with 60-90% moderate/strong 
( + + I + + +) nuclear staining, in contrast to the more homogenous strong 
nuclear staining of the recurrenee and the metastases (100%)(Figure I, C-F). 
Cytoplasmic localisation of the P53 protein was only observed in sample I for 
P53, when using antibody 1801, in samples land II, when using antibody 
001. A sporadic nuclear overexpression of MOM2 was seen in the metasta-
tic samples (regarded as negative, table 2) but no nuclear staining was obser-
ved in sample land 11. However a gramtlar cytoplasmic staining was obser-
ved in sample I. BAX was highly (90%) expressed in the cytoplasm of the 
primary, local recurrence and first metastatic tumour but the intensity decrea-
sed from strong in sample I to moderate in samples II and IV; chest wall 
tumour sample V however demonstrated a low BAX expression « 10%). 
BCL2 was found to be highly expressed in sample I (70%), in contrast to a 
10w expres sion of the same antibody in the other tumour samples. No expres-
sion of P21 was observed in all tumour samples, although granular cytoplas-
mic staining was noticed in sample I. In the benign breast material only 
expression of BAX and BCL2 in the ductal epithelium was observed (Tabie 
2). 
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TabJe 2. bmmmollistocllemical expressioll of fhe different markers ill tlle tissue of file var/Olls 
tumour samples Gild benign breas! tissue. 
markers 
Ki-67 
P53 1801 
DOl 
MDM2 
BAX 
BCL2 
P21 
primary reCUf- benign metastasis metastasis 
tumour reoee breast lung chestwall 
I 
" 
III IV V 
% % % % % 
30 30 neg 60 50 
60-90* 100 neg 100 100 
90 90 neg 100 100 
neg neg neg neg neg 
90 90 30 90 <10 
70 <10 100 20 <10 
neg neg neg neg neg 
*111 fitis sample a heterogellOfls staillillg pattem was fOlil/d 
PCR-SSCP alld sequellcillg aJwlysis 
TP53 gene mutation analysis was performed using PCR-SSCP and sequencing 
techniques. TP53 base alterations in exons 4 tllfough 9 were tested. The 
primary tumour (I), local recurrence (II), adjacent normal (III) and the two 
metastases (IV, V) were examined. An altered migration pattem on SSCP, 
indicative of a mutation, was observed in exon 8 of samples I, Il, IV and V. 
Sample III, which contained DNA from adjacent normal breast tissue silOwed 
no alteration in the migration pattern. PCR products with this altered migrati-
on pattern were subsequently analyzed by cycle sequencing. A missense point 
mutation ÇGT>IGT at codon 273, shown in Figure IB, resulting in an 
amino acid change from Arg- > Cys (R> C) was observed in those tumour 
samples (I, Il, IV and V). 
7.6 DISCUSSION 
Recent studies (6,12,18,22) on phyllodes tulnourS have shown that the pre-
sence of tumour at the surgical margin is the major determinant of local 
recurrence or development of metastasis, whereas the histological features of 
these tumours are of secondary importance with regat'd to prognosis. This 
prompted our study on modern prognostic features in phyllodes tumours to 
investigate their possible use in prediction of more aggressive tumour sub-
sets. The case presented here, was one of a group of 20 patients with phyllo-
des tumours of which frozen material was available for immunohistochemical 
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and molecular biological analysis. In four cases (one histologically malignant, 
two borderline and one benign) an overexpression of P53 (> 10 %) was 
found. Frozen material was available of only three tumour samples for gene 
analysis (data not shown). Only the case presented here (histologieally malig-
nant) showed a TP53 gene mutation. Over-expression of P53 protein was not 
only seen in the primary but also in the recurrent and in the two metastatie 
tumour samples. Furthennore in all tumour samples of this patient, the same 
TP53 gene mutation, e.g. Arg273Cys, was detected. A sample of benign 
breast tissue of this patient showed no gene alteration, indicating that this was 
an acquired TP53 gene mutation and not a germline mutation. This is the 
first report on TP53 mutations in phyllodes tumours. Analysis of the TP53 
crystal structure indieated that some of the commonly mutated basic residues 
either are important for stabilization of the p53-DNA complex (e.g. Arg175 
and Arg249) or directly interact with the DNA (e.g. codons Arg248 and 
Arg273)(5). Codon 273 of TP53 is one of the most frequent missense mutati-
on sites found in human cancers. Wild-type TP53 has been shown to be a 
sequence-specific transactivator for promotors containing the TP53 binding 
site, including GADD45, cyclin 9, MDM2, P21 and BAX (11). Therefore 
we have studied P53-dependent induction of MDM2 and of P21 .. wdpl ; a 
potent inhibitor of cyclin dependent kinases. P21 has been shown to be indu-
ced by radiation (la) or transforming growth factor Jl (TgFJl). In contrast to 
the high P53 expression sporadic nuclear overexpression of MDM2 was only 
seen in the two metastatic tumour samples. This is consistent with the analy-
sis of the TP53 and MDM2 genes in sarcomas which shows that no MDM2 
alterations are found in sarcomas with TP53 gene mutations (20). The cyto-
plasmic staining of MDM2 whieh we observed in sample I has not been 
described elsewhere in sarcomas, although a faint cytoplasmic staining is 
mentioned in epithelial breast cancer studies (17). In the presence of mutated 
TP53 gene no induction of P21 protein is expected, whieh is consistent with 
our findings of negative nuclear staining of P21 in both primary and meta-
static tumour tissue, see Table 2. Cytoplasmic staining of P21 was observed 
in sample I, and not present in the other tumour samples. 
The second possible mechanism of growth suppression by wild-type P53 is 
explained by its promotion of apoptosis. The sensitivity of cells to apoptotic 
stinmli is considered to be regulated by the ratio of BAX:BCL (2,14). Inte-
restingly, cells with high BAX expression are found to be associated with 
high response to chemo- and radiotherapy (15). 
We have studied BAX expression patterns and the expression of its dimeriza-
tion partner BCL2. The observed overexpression of BCL2 in sample I may 
have caused blocking of apoptosis and therefore clonal selection of radiothe-
rapy resistant cells, however this is not in concordance with the negative 
BCL2 expression found in the recurrences. In this case also strong cytoplas-
mie BAX staining was found in the primary tumour different from the mode-
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rate staining in the other tumour samples. As yet, we have no unequivocal 
explanation for the strong BAX staining in the primary tumour and the lack 
of response to radiotherapy. 
In conciusion, mutated P53 in th is tumour, with its associated incompetence 
for DNA repair , cycie arrest and apoptosis may have lead to a cional selecti-
on of more aggressive tumour cells aftel' DNA damage (J 9) and therefore 
different expression levels of the studied proteins in addition to radioresistan-
ce. The case presented here illustrates that detection of TP53 gene alterations 
may offer new prognostic information in phyllodes tumours of the breast. 
Further and larger studies on TP53 and its regulated proteins will provide 
more insight of the prognostic value of these proteins in phyUodes tumours. 
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CHAPTER 8 
GENERAL DISCUSSION AND CONCLUDING REMARKS 
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In this chapter the clinical significanee of histologieal, IH and IC determined 
parameters in breast tumours analyzed in the foregoing studies, will be 
discussed. 
8.1. llIIroduction 
Early detection of breast cancel' has reduced the size of the average breast 
tumour at diagnosis. in the future new diagnostic and surgical procedures will 
again influence the amount of tissue available for diagnosis and IH and 
biochemical assays. For instanee, ultrasound localised biopsies used for the 
diagnosis of small non-palpable tumours detected by mmnmographic screening 
may in the future be replaced by diagnosis with stereotactic core needie biopsy, 
leading to a further reduction of tumour tissue. 
Lately, the need of complete axillary dissection has been questioned, because 
of high morbidity of the procedure caused by lymphedema and neuropathy of 
the involved arm. For this reason exmnination of the so-called sentinel node(s), 
defined as the first node draining the primary tumour in the regional Iymphatic 
basin' , is being advocated and may weil replace total axillary dissection in the 
future. As Iymph node status has long been the golden standard in determining 
the prognosis of a breast cancel' patient, not knowing the nodal status of a 
patient wiII have important repercussions for breast cancer management, and 
wiII enhance the need for other valid prognostic factors. 
In addition to these changes in diagnostic and surgical procedures, peri-operative 
chemotherapy is being advocated even in the group of node-negative patients 
and peri-operative hormonal therapy in postmenopausal women. These 
developments again wiII reduce the amount of tllmour tissue available for 
additional techniques, especially for biochemical assays. These considerations 
wiII make the use of immunological techniques more appealing for assessment 
of clinically significant cell biological markers, also on cytological material, 
particularly when no primary surgery is performed. Moreover, these markers 
will gain impact when strong prognosticators like lymph node status are no 
longel' available. 
8.2. Histo/cytological grading alld typillg. 
The prognostic value of histological grading has been studied widely and been 
accepted as an important predictive parameter of the biological behaviour of 
breast carcinomas, provided that strict criteria are followed 2.3,4. Likewise, it 
has been demonstrated that histologically typing of breast carcinomas has 
prognostic significance'·6. In addition Pereira et al has shown that these 
parameters are used together even more accmately predicted prognosis 7 • In 
view of these findings, we graded the different types of breast cancel' according 
to Bioom and Richardson and modified according to Elston4 and found grade to 
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be an important parameter in univariate analysis (chapter 6). Moreover , we 
found the 17 receptor negative tumours to be grade III tumours. They were 
characterised by a high percentage of Ki-67 positive cells. In addition, 
histological subtypes, such as cribriform, colloid and tubular were all found to 
be receptor positive (chapter 5 and 6) while demonstrating low Ki-67 activity. 
These observations emphasise the actual importance of grading and typing. In 
the light of future developments, when lymph node status is not longer known, 
it may be important to implement these parameters in clirtical breast cancer 
management. 
8.3. Proliferative activity 
The proliferative activity of tumour cell populations, as defined by different 
approaches has been found to provide information about prognosis. Since some 
of the methods like the labelling techrtiques are laborious and not suited for 
routine laboratory practice, the use of innnunohisto/cytochemistry has become 
more appealing. The monoclonal antibody Ki-67 defining a nuclear antigen 
associated with proliferation, was at first only applied to frozen tissue. We 
found that this anti body (chapter 2) could easily be used on cytologicalmaterial 
and that cytological assessment of Ki-67 growth fractions led to similar results 
as found in cryostat sections of corresponding tumours (chapter 3). Moreover, 
in concordance with thymidine labelling studies8, a relationship between 
subtypes of breast cancer and proliferative activity was demonstrated (chapter 
3 and 6). Infiltrating ductal carcinomas were shO\ving the highest activity, and 
subtypes like tubular and colloid carcinomas were showing the lowest. 
Numerous papers have been published about the prognostic value of the Ki-67 
determined growth fraction 9,10,11,12. Correlations have been demonstrated 
between Ki-67 scoring, the S-phase fraction as determined by flow cytometry 
and mitotic count 9,13,14. Considering these facts, Ki-67 iIrununostaining can 
be seen as a rapid and inexpensive method of assessment of the proliferative 
index, and may be helpfui in selecting patients for endocrine therapy (slowly 
proliferating tumours) or chemotherapy (rapidly proliferating tumours). 
8.4. Steraid receptars. 
The biochemical assessment of ER and PR is weIl recognized as aid for 
predicting prognosis and choice of therapy. We found, like in other 
studies",I" a significant correlation between biochemically obtained data and 
immuno-histochemically obtained data for ER and PR (chapter 6). Likewise, the 
prognostic value, as for disease free survival, of ERIPR detected by either 
method was similar. We confirmed the prognostic value of ER in multivariate 
analysis, Areliabie detection of these receptors not only in histological but also 
in FNA material is feasible, as shown in clIapter 4. The clinical significance of 
AR is poody understood. The widespreact expression of AR in breast cancer 
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(incidence of 76%), demonstrated in chapter 5 and 6, and later confirmed by 
Isola l7 and HalP' suggests that this receptor may be of biological importance 
in breast cancer. Unfortunately, we were not able to determine the additional 
therapeutical relevance of AR positivity as the number of patients receiving 
hormonal treatment for advanced disease was too small to study this 
relationship. Since Birrell et al. 19 found a correlation between AR level in the 
primary tumour and response to medroxyprogesterone acetate therapy in 
lymphnode positive breast cancers, this finding may indicate that activation of 
AR function may act as an important inhibitor of breast cancer growth in vivo. 
8.5. TP53 alteratioJls 
TP53 alterations have been described in numerous tumours including breast 
cancer and sarcomas. Mutations give rise to a conformationally altered protein, 
stably expressed at high levels, which can currently be routinely determined by 
immunohistochemistry. TP53 alterations appear to independently predict poor 
prognosis in breast cancer patients20•2I , but have, as yet not been studied in 
phyllodes tumours of the breast. In our ongoing studies on phyllodes tumours, 
not only TP53, and Ki-67 but also TP53 regulated proteins were examined using 
IR and molecular biological techniques. In one case of a patient with a 
malignant phyllodes tumour of the breast (chapter 7), we found not only high 
expres sion of both Ki-67 and P53 protein in the primary tumour, recurrence and 
metastases, but also the same TP53 gene mutation in all samples. Since this 
patient died within two years after diagnosis, TP53 gene alterations, like in 
breast cancer, may represent an important prognosticator , indicating a poor 
prognosis in phyllodes tumours. 
8.6. Qllality aSSllraJlce iJl illIlIlllllOilisto/cytocilemistlY 
When we wish to implement immunohisto-/cytochemical detected parameters in 
breast cancer management, several problems have to be considered. Among 
others, we mention the considerable variation in scoring methods and cut-off 
points for various parameters used in the literature. An example of this problem 
is the fact that we, like Bouzubar and VeroneseIO,1I have taken a Ki-67 score 
equal to or over 20% as a cut-off level of high and low proliferative activity 
while Railo and Isola have used a cut-off level of ten percent in their assays9.I3. 
These differences may have considerable impact in survival analyses, and inter-
laboratory studies are needed to validate the different methods. 
Not only differences in cut-off points, but also in detection techniques and in 
methods of material processing, fixation and storage do exist, all influencing the 
detectability of an antigen. This latter is especially true for immunostaining in 
cytology22, and makes comparison of studies cumbersome, if not impossible. 
To standardize immunostaining in cytology, we embarked on a study to analyze 
the influence of different working procedures. We found that, depending on the 
localisation of the antigen (nuclear, cytoplasmic or membranous) different 
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methods of material processing are required. These observations iIIustrate the 
need for quality controlled standardized procedures to ascertain reproducible 
immunostaining results. In view of these facts, the pathology committee of the 
EORTC Breast Cancer Cooperative Group has set up a EORTC pathology 
collaborative group to coordinate activities concenting standardization of metho-
dologies, cut-off points etc. 
8.7. Implemellfation of cell biological markers in clinical decision-makillg 
Many of the cell biological markers described have prognostic value in 
univariate analysis but when multivariate analysis is applied these parameters in 
general, add very IiWe to prognostic modeis. This was again demonstrated in 
chapter 6: in univariate analysis AR as weil as ER, tumour size, Iymph node 
status, grade and Ki-67 proved to be significant prognostic factors for DFS, 
multivariate analysis, however silOwed Iymph node status, tumour size and ER 
status to be the only independent prognostic factors for DFS within this model. 
Table 1 
authors 
Rosen 
Dixon 
Galea 
Meyer 
Silvestrini 
Lipponen 
Table2 
authors 
Raaymakers 
Schmitt 
time (yrs) 
18 
20 
15 
10 
6-10 
4 
long-term prognostic factors 
N status grade type size growth 
fraction 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
time(yrs) short-term prognostic factors 
3 
2 
ER 
+ 
+ 
PR 
+ 
It should be noted however, that time after first treatment is another important 
factor in determining the prognostic value of a parameter. Several authors have 
demonstrated the changing importance of prognostic factors during longterm 
follow up. Tumour size, Iymph node status, grade and growth fraction are found 
to be long term prognostic factors'·2J·24.25.26(Table 1). Estrogen receptor and 
PR lose their prognostic significance after the first few years after 
surgery27'''(Table 2). 
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These observations emphasize the fact that for implementation of new 
parameters follow-up studies over longer periods of time in combination with 
multivariate studies are necessary to validate the use of these parameters. 
Moreover quality assurance programs will be needed to standardize the various 
procedures. 
8.8. CONCLUDING REMARKS. 
In the last decade our knowledge of the biological behaviour of breast cancer 
has increased remarkahly. Moreover , refinements of treatment, have resulted in 
improvement of five year survival. Nonetheless overall hreast cancer mortality 
rates have not improved significantly in the last 20 years. Conventional 
parameters, like lymph node status, tumour size, grading and typing are still of 
great importance, hut additional prognostic parameters are urgently needed, 
especially for node negative patients hecause of a trend toward a general use of 
adjuvant therapy". As stated earlier, new treatment modalities and reduction 
of tumour tissue availahle for diagnostic and prognostic information, necessitate 
the maximum yield of information from histological but also from cytological 
specimens. This will especially be tnie when systemic therapy is going to be 
applied prior to surgery and aspirates will be the only tissue available for 
determination of predictive and prognostic factors. We have demonstrated that 
proliferative activity, can easily he determined on cytological/histological 
material, provided that standardized methods, also in scoring are being applied. 
The same is true for the detection of hormone receptors and TP53. The 
determination of a comhination of these parameters may help to identify patients 
with a low/high probahility of risk of tumour recurrence. In addition the bellefit 
of hormonalor chemotherapy can be anticipated. The Nottingham group has 
indeed shown in a large group of patients over a long period of time (15 years) 
that a comhination of different independently significant prognostic parameters 
(lymph node status, grade and size) can predict survival of an individual patient 
more accurately than using any of these factors individually". Likewise they de-
monstrated that another index (a combination of grade, ER, site of initial 
metastasis and disease free interval) could he used for a group of patients \Vith 
metastatic disease to predict the effect of hormolle therapy3o. Clark29 on the 
other hand comhined age, lymph node status, S-phase, tumour size and ER/PR 
values in a model to define the poor risk group. In addition new parameters like 
TP53 expression may he used to predict resistance to specific therapies. We 
conclude therefore that time has come for the clinical implementation of those 
parameters, which have already proven their prognostic/predictive value, in 
order to avoid unnecessary treatment, especially in the case of node negative 
patients. 
92 
Referellces 
1. AlbertiniJJ, Lyman GH, Cox C et al. Lymphaticmappingand sentinel node biopsy in the patien! 
with breast cancer. JAMA, 276: 1818-1822,1996. 
2. Fisher ER, Redmond C, Fisher B. Histologie grading of breast cancer. Pathol AI/IIlI, 15: 239-
251,1980. 
3. Rosen PP, Groshen S, Saigo PE, Kinnc DW. Hellman S. Pathological prognostic factors in 
stage I (flNoMo) and stage II (TINIMo) breast carcinoma: a study of 644 patients with rnedian 
follow-up of 18 years. J Clil/ Ol/col, 7: 1239-1251,1989. 
4. Elston CWt Ellis 10. Pathological prognostic factors in breast cancer. I. Tllc value of 
histological grade in breast cancer: experienee from a large study with a long lerm follow up. 
Histopathology, 19: 403-410, 1991. 
5. Elston CW, Gresham GA, Rao as, et al. Thc Cancer Research Campaign (Kings/Cambridge) 
trial for early breast eaneer~ pathological aspeets. Br J Cal/cer, 45: 665-669,1982. 
6. DixonJM, Page DL, AndersonTJ et al. Long term survivorsafter breast eaneer. Rr J Surg, 72: 
445-448,1985. 
7. Pereir-a A, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer IV: 
Should you be a typer or a grader? A comparativestudy of two histological prognostic features in 
operablebreast careinoma. Histopathology, 27; 219-226,1995. 
8. Meyer JS, Friedman E, McCrate MM, Bauer WC. Predictionof early course of breast carcinoma 
by thymidine labeling. Cmlcer, 51: 1879-1886,1983. 
9. Railo M, LundinJ, Haglund C, el al. Ki-67, P53, ER, Ploidy and S-phase as prognosticfactors 
in Tl node negative breast cancer. Acta Ollcologica, 36: 369-374, 1997. 
10. Bouzubar N, Walker KJ, Griffiths K, et al. Ki-67 immunostaining in primary breast cancer: 
pathologicaland clinical associations. Rr J Cal/eer, 59: 943-947, 1989. 
11. Veronese SM, Gambacorta M, Gottardi 0, et al. Proliferation index as prognostic marker in 
breast cancer. Cal/cer, 71: 3926-3931,1993. 
12. WintzerHO, Zipfel I, Schulte-MontingJ, et al. Ki-67 immunostainingin humanbreast tumours 
and its relationshipto prognosis. COIlcer, 67: 421-428, 1991. 
13. Isola JJ, Helin JH, Heli MJ. Kallioniemi OP. Evaluation of cell proliferation in breast 
carcinoma. Comparison of Ki-67 immunohistochemicalsrudy, DNA flow Cytometric analysis and 
mitotic count. Caneer, 65: 1180-1184,1990. 
14. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic 
figure index and tumour grade in breast carcinomas using the navel ~paraffîn"-reactive MIBI 
antibody. HI/lllal/ PatIlol, 25: 337-342, 1994. 
15. Heubner A, Beek T, Grill HJ, Pollow K. Comparison of immunocytochemicaloestrogen 
receptorassay, oestrogenreceptorenzyme inmlUnoassay, and radioligand-Iabeledoestrogen receptor 
assay in human breast eaneerand uterine tissue. Callcer res, 46 (suppl): 42912-42952, 1986. 
16. Alberts SR, Ingle JN, Roche PR et al Comparison of estrogen receptor determinations by a 
biochemical Iigand-binding assay and immunohistochemical staining with monoelonal antibody 
ERID5 in females with lymph node positive breast careinoma entered on two prospectiveclinical 
trials. Cal/cer, 78: 764-772,1996. 
17. Isola JJ, Immunohistochemical demonstration of androgen receptor in breast caneer and its 
relationship to other prognostic factors. J Palhol, 170: 31-35, 1993 
18. Hall RE, Aspinall JO, Horsfall DJ et al. Expression of the androgen receptor and an androgen-
responsiveprotein, apolipoproteinD, in human breast eancer. Br J Cancer, 74: 1175-1180,1996. 
19. DirreIl SN, Rode DM, Horsfall DJ, et al. Medoxyprogesterone acetate therapy in advanced 
breast eaneer: the predictive value of androgen receptor expressioll. J Clill Olleol, 13: 1572-1577, 
1995. 
20. Elledge RM, AUred DG. The p53 tumoursuppressorgenes in breast cancer. Breast Cal/eer Res 
Treat, 32: 39-47, 1994. 
93 
21. Berns EMJJ, Klijn lOM, Smid M, et aI.TP53 and myc gene alterations indepcndently prcdict 
pOOf prognosis in breast cancer patients. Genes, Chrol1losom Cancer, 16: 170-179, 1996. 
22. Kuenen-BoUJneesterV, De Bruijn EMCA, Henzen-LogmansSc. Immunocytochemical staining 
of effusions; an externalqualitycontrol study in The Netherlands. CytopatllOlogy, 8: 248-255, 1997. 
23. Galea MH, B1amey RW, EIsIon CE, Ellis 10. Thc Nottingham Prognostic Index in primary 
breast cancer. Breast Cancer Res Treat, 22: 207-219,1992. 
24. LipponenP, Aaltomaa S, Eskelinen M, et al. Tlte changing imporlanceof prognostic factors in 
breast cancerduring long-term follow-up. lilt J CO/leer, 51: 698-702, 1992. 
25. Silvestrini R, Daidone MG, Luisi A, et al. Cel! proliferation in 3.800 node -negative breast 
cancer: consistency over time of biological and clinical information provided by JH-Thymidine 
labelling index. /111 J Callcer, 74: 122-127, 1997. 
26.Meyer JS, Province MA. S-phase fraction and nuclear size in long term prognosis of patients 
with breast cancer. Callcer, 74: 2287-2299,1994. 
27. Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumour biological 
factors urokinase (uPA), PAI-l and steroid receptor status in primary breast cancer. Br J Callcer, 
76: 306-311,1997. 
28. Raemakers JMM, Beex LV AM, Koenders AlM. Disease-free interval and estrogen receptor 
activity in tumour tissue of patients with primary breast cancer: analysis after long-term follow-up. 
Breast Callcer Res Treat, 6: 123-130,1985. 
29. Clark OM. Do we really oeed prognoslic factors for breast cancer? Breast Callcer Res Trea!, 
30: 117-126,1994. 
30. RobertsonJFR. Dixon AR, NicholsonRI, Ellis 10, Elston CW. B1amey RW. Confirmationof 
a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast 
Callcer Res Treat, 22: 221-227,1992. 

95 
Figure 4, Chapter 3 
Comparisoll of Ki-67 immtmosloilling of frozell sec/lons (A, C) alld FNA slI/ears (B,D) of the some 
tull/our. A + B: dlle/al carcilloma, C + D: llllICÎI/OUS carCÎllomo 
Figure I . Chapter 7 
A: fJE-slail/ing of prima!)' IIImour: high cel/ularit)' of Ilie stromo lVi/IJ Iltlc/ear polymorpllism 
B: Sequellce mmlysis of exol/ 8 a/TP53. Tlle muro/ioll is jl/(licated by the afrol\' (Arg273Cys);1/ the 
right IOlle. 111 the left IOlle wild-type TP53 is sl/OII'/I. 
C: Imllllllloslaillillg wit" P53 (1801) of tlle primary tull/our: moderate, heterogellOils staillillg wirh 
lIuelear alld cytoplasmic localisatioll. 
D: Iml1lrmostaillillg witll P53 (1801) of tlle reclirrence: slrollg n/lelear staillillg 
E and F: Jmmulloslaillillg witlt P53 (1801) of rlle 111'0 metastases, E limg (sample IV), F chestwall 
(sample V): slrong IlIleleor sta;lIillg comparable 10 D. 
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CHAPTER 9 
SUMMARY 
The aim of this thesis was to analyse the applicability of immunocytochemistry 
(IC) on fine needie aspirations (FNA) of breast tumours and to assess the 
clinical value of not only IC, but also IH determined ceU biological parameters. 
The growth fraction of a breast tumour as reflected by its mitotic activity is 
considered to be an important prognostic indicator. The application of the 
monoelonal antibody Ki-67, defining a nuelear antigen present throughout the 
ceU cyele enables a simple evaluation of the growth fraction of a tumour. Initial 
studies with this antibody were confined to tissue sections of breast tumours. 
Since the initial diagnosis of breast cancer in general, is made on FNA smears 
and patients are increasingly given chemotherapy prior to surgery, the feasibility 
of the determinatioll of proliferative activity in FNA smears was examined. In 
chapter 2 we describe a preliminary study in which FNA smears were IC 
stained with monoelonal antibody Ki-67. A weU-defined nuelear 
immunoreactivity was obtained in a variabie proportion of the ceUs aUowÎllg a 
reproducible quantitation of Ki-67 positive ceUs in these smear preparations. A 
low median percentage of 0.4 % Ki-67 positive ceUs was found in benign 
aspirates as compared to the much higher median Ki-67 score of 7.9 in aspirates 
derived of breast cancers. A significantly higher median Ki-67 score of 12.3 
was demonstrated in the FNA smears of breast cancer ceUs that had 
metastasized. This latter finding is inline with the view that rapidly proliferative 
breast cancers have a prognosticaUy less favourable behaviour. 
The reliability of Ki-67 immunostaining in FNA material was subsequently 
assessed in chapter 3. We compared the results of the Ki-67 determined growth 
fraction in FNA material and cryostat sections of corresponding tumours. Ki-67 
scores of FNA smears correlated weU (r= 0.79) with the values obtained in the 
frozen sections. In addition, we observed both on frozen sections and FNA 
smears that the Ki-67 scores differed for the various histological types of breast 
cancer. These latter results confirmed previous published data employing in 
vitro incorporation of radioactively labeUed thymidine in breast cancer tissue 
fragments. 
The potential implementation of IC determined prognostic factors in clinical 
decision-making requires a highly reproducible and reliable technology, which 
can only be achieved by standardization of handling and processing of the 
diagnostic material and a robust technique of immunostaining based on well-
characterized and generaUy available reagents. In addition, the scoring system 
should not be subject to great inter-obselver variation. ActuaUy, substantial 
variations in the values of a given parameter can be found in the literature. In 
chapter 4 we analysed the influence of material processing, fixation and storage 
of FNA aspirates on IC staining results. We developed a standardized method 
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for achieving reproducible immunostaining results of optimal quality for nuclear 
antigens. Employing this method, a high concordance of IC results obtained in 
histological material and corresponding cytological material of 10 breast 
carcinomas was observed. 
The presence and frequency of estrogen receptors (ER) and progesterone 
receptors (PR) in breast cancer has been examined extensively both by 
biochemical and immunohistochemical (lH) methods. Much less was known 
about the frequency of androgen receptors (AR) in breast cancers. In chaptel' 5 
AR expression in 100 breast carcinomas was determined using a recently 
developed monoclonal antibody specific for AR. Seventy-six percent of these 
breast cancers were AR positive, while nine percent of the tumours expressed 
AR without concomitant ER or PR expression. Tumour grade was not only 
inversely related to ER and PR expression, but also to AR expression. 
Moreover, all receptor negative tumours were poorly differentiated (grade III) 
tumours. 
Although the prognostic role of oestrogen receptors (ER) and progesterone 
receptors (PR) in breast cancer has long been established, both with regm'd to 
endocrine therapy response and survival, Iittle information was available as to 
the prognostic impact of AR expression in breast cancers. To establish the 
clinical significance of the presence of AR in breast carcinomas we studied 153 
cases, with a median follow-up time of 46 months, as described in clwptel' 6. 
In addition, the prognostic impact of the Ki-67 score was assessed and several 
c1inico-pathological parameters were recorded. The latter included tumour stage, 
patients' age, and disease free survival (DFS). ER and PR expression was 
quantified both by IH in frozen tissue sections and by biochemical enzyme 
immunoassay in cytosol preparations, while AR expression was assessed 
senjiquantitatively only by IH. Biochemically assessed ER and PR levels 
correlated weil with IH determined ER and PR scores, respectively. In 
univariate analysis AR as weil as ER, and Ki-67 score in addition to the 
patllOlogical parameters tumour size, Iymph node status, and tumour grade all 
proved to be significant prognostic factors for DFS. Multivariate analysis, 
however, showed Iymph node status, tumour size and ER status to be the only 
independent prognostic factors. Unfortunately, we could not study the 
relationship between AR expression and response to hormonal therapy, since in 
this series the number of patients receiving hOl'lnonal treatment for advanced 
disease was too smal I. 
A nowadays frequently investigated prognostic parameter is the TP53 protein, 
a product of the TP 3 tumour suppressor gene. Although its overexpression at 
the protein level and the OCCUl'1'enCe of point mutations in the TP53 gene has 
been studied extensively in breast cancers, the occurrence of similar aberrations 
in the less common phyllodes tumours of the breast has not been reported. In 
chaptel' 7 a case of a metastasized phyllodes tumour of the breast was studied 
with regard to IH determined Ki-67 score, TP53 protein expres sion and its 
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regulated proteins, and TP53 gene alterations. Next to TP53 overexpression, a 
high Ki-67 score was observed not only in the primary tumour but also in the 
recurrent tumour and in the tumour metastases. In all tumour samples an 
identical TP53 gene mutation, i.e. Arg273Cys, was detected. Apparently, 
primary tumour, recurrent tumour and metastases represent the progeny of a 
single precursor cell. In a larger series of phyllodes tumours the prognostic 
impact of TP53 gene mutations remains to be established. 
In chapter 8 we discuss the consequences of new diagnostic and therepeutical 
procedures with regat'd to breast Cancel' management. We conclude that these 
changes wil! make it even more important to use IH and IC for the 
determination of cell biological parameters in breast cancer. 
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SAMENVATTING 
De bedoeling van het in dit proefschrift bescln'even onderzoek was om de 
blUikbaarheid van immunologische technieken in de cytologie, met name in 
punctie materiaal van mamma tumoren, te onderzoeken en de klinische betekenis 
van immunohisto-/cytochemisch bepaalde celbiologische parameters te testen. 
De groeisnelheid van een tumor gekarakteriseerd door het aantal cellen in 
deling, wordt als een belangrijke prognostische parameter beschouwd. Het 
geblUik van het monoclonale antilichaam Ki-67, dat een kern antigeen aantoont 
dat uitsluitend in de kern van delende cellen wordt gevonden, stelt ons in staat 
om op een simpele manier de groeifractie van een tumor te bepalen. 
Aanvankelijk werd dit antilichaam door andere onderzoekers alleen geblUikt bij 
onderzoek van histologisch materiaal van mammatumoren. Aangezien de eerste 
diagnose van borstkanker in het algemeen gesteld wordt op punctie materiaal, 
werd door ons onderzocht of ook in cytologisch materiaal met behulp van Ki-67 
de delingsactiviteit van een mammacarcinoom kon worden bepaald. In hoofdstuk 
2 beschrijven we een eerste studie waarin cellen afkomstig van puncties 
immunocytochemisch werden onderzocht met behulp van het monoclonale 
antilichaam Ki-67. Er werd in een wisselend aantal van de cellen een duidelijke 
immunoreactiviteit van de kern verkregen, wat een reproduceerbare bepaling 
van de hoeveelheid Ki-67 positieve cellen mogelijk maakte. Een laag mediaan 
percentage van 0.4 Ki-67 positieve cellen werd gevonden in uitstrijken 
afkomstig van punctaten van goedaardige mamma lesies in vergelijking met de 
veel hogere mediane Ki-67 score van 7.9 in punctie materiaal afkomstig van 
mamma carcinomen. Een significant hogere mediane Ki-67 score van 12.3 werd 
gevonden in punctie materiaal van uitgezaaide mammacarcinomen. Deze laatste 
bevinding past bij de gedachte dat snel delende mammacarcinomen een 
prognostisch minder gunstig gedrag vertonen. De betrouwbaarheid van de 
inununocytochemische kleuring met Ki-67 op punctaten werd vervolgens getest 
in hoofdstuk 3. Wij vergeleken de resultaten van de met Ki-67 bepaalde 
groei fractie in punctaten met die bepaald in vriescoupes van weefsels van 
dezelfde tumoren. De Ki-67 scores van het punctie materiaal correleerden goed 
(r=0.79) met de waarden verkregen in vriesmateriaal. Bovendien vonden we 
zowel in de vriescoupes als in cytologische uitstrijken dat de gevonden Ki-67 
scores verschillend waren voor de verschillende typen mamma carcinoom. Deze 
laatste resultaten bevestigden eerder gepubliceerde data waarbij radioactief 
gelabelde thymidine in vitro in mamma carcinoom weefsel werd geincorporeerd, 
en waarbij eveneens bleek dat bepaalde typen mammacarcinoom een lagere 
groeisnelheid vertoonden. 
De mogelijke implementatie van immunocytochemisch bepaalde prognostische 
factoren in de klinische besluitvorming vereist een goed reproduceerbare en 
betrouwbare techniek. Dit kan alleen worden bereikt door standaardisatie van 
het verwerken van het diagnostisch materiaal en een betrouwbare techniek van 
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immunokleuring gebaseerd op goed gekarakteriseerde en algemeen verkrijgbare 
reagentia. Aangezien belangrijke variaties in waarden van de verschillende 
parameters worden gevonden in de literatuur, moet bovendien het scoring 
systeem niet onderhevig zijn aan een te grote variatie tussen waarnemingen 
gedaan door verschillende onderzoekers. In hoofdstuk 4 analyseerden wij de 
invloed die de materiaal verwerking, fixatie en de manier van bewaren hebben 
op de expressie van in punctie materiaal, immunologisch bepaalde prognostische 
parameters. Wij ontwikkelden vervolgens een gestandaardiseerde methode om 
kernantigenen immunologisch te kleuren, die goed reproduceerbaar was en van 
optimale kwaliteit. Bij toepassing van deze methode, werd een goede 
overeenkomst gevonden tussen gevonden immunocytochemische resultaten 
bepaald in histologisch materiaal en die bepaald in het corresponderende 
cytologische materiaal bij 10 mamma carcinomen. 
Er is zowel biochemisch, als immunohistochemisch uitvoerig onderzoek gedaan 
naar de aanwezigheid, ook kwantitatief, van oestrogeen -(ER) en progesteron 
receptoren (PR) in mamma carcinomen. Veel minder is bekend ten aanzien van 
de aanwezigheid van androgeen receptoren (AR) in deze carcinomen. In 
hoofdstuk 5 werd de AR expressie bepaald in 100 mamma carcinomen met 
behulp van een recent ontwikkeld monoclonaal antilichaam specifiek voor AR. 
Zes en zeventig procent van deze mamma carcinomen toonde AR expressie, 
bovendien werd in negen procent van de tumoren AR expressie gevonden, 
zonder dat er sprake was van ER of PR expressie. Daarnaast werden alle 
tumoren histologisch gegradeerd. Het bleek dat de tumor graad omgekeerd was 
gerelateerd aan ER en PR expressie maar ook aan AR expressie en dat alle ER, 
PR en AR negatieve tumoren, graad III tumoren bleken te zijn. 
Hoewel de prognostische betekenis van ER en PR in borstkanker reeds lang 
bekend is, zowel wat betreft de respons op hormoon therapie (betere respons bij 
positieve ER en PR), als wat betreft overleving, is nog weinig bekend ten 
aanzien van de prognostische betekenis van AR expressie in mamma 
carcinomen. Om de klinische betekenis van de aanwezigheid van AR in 
borstkanker te analyseren, onderzochten we 153 mammacarcinomen met een 
gemiddelde follow-up van 46 maanden, zoals beschreven in hoofdstuk 6. 
Daarnaast onderzochten we de prognostische betekenis van de Ki-67 score en 
werden verschillende klinische en pathologische parameters bepaald, zoals 
leeftijd, de tumor stagering en de ziektevrije periode. ER en PR expressie werd 
kwantitatief bepaald zowel immunohistochemisch op vriesmateriaal als 
biochemisch met de enzyme immunotechniek, terwijl de AR expressie alleen 
immunohistochemisch werd bepaald. Biochemisch bepaalde ER en PR expressie 
correleerde goed met immunohistochemisch bepaalde ER en PR scores. In 
univariaat analyse bleken AR, evenals ER en Ki-67 score alsmede de 
pathologische parameters tumor grootte, lymfklier status en tumor graad 
allemaal significant prognostische factoren wat betreft de ziekte vrije periode te 
zijn. Multivariaat analyse toonde echter dat alleen de lymfklier status, tumor 
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grootte en ER status onafhankelijke prognostische factoren waren. Helaas 
konden we niet de relatie tussen AR expressie en respons op hormonale therapie 
onderzoeken, aangezien in deze patienten serie het aantal patienten dat 
hormonale therapie had gekregen voor gemetastaseerde ziekte, te klein was. 
Bepaalde genen, de zogeheten tumor suppressor genen, onderdtukken het 
ontstaan enJof de progressie van kanker cellen. Een voorbeeld van een dergelijk 
gen is het TP53 gen. Ofschoon zowel de overexpressie van het TP53 eiwit (een 
produkt van dit gen) als de mutaties die in dit gen kunnen voorkomen, 
uitgebreid zijn onderzocht in mammacarcinomen, zijn er nog geen studies 
gedaan naar dergelijke mutaties in de minder voorkomende phyllodes tumoren 
van de borst. In hoofdstuk 7 wordt een geval van een gemetastaseerde phyllodes 
tumor beschreven waarbij niet alleen de immunohistochemisch bepaalde Ki-67 
score werd bepaald maar ook de TP53 eiwit expressie en de door dit gen 
gereguleerde andere eiwitten. Bovendien werd gekeken naar TP53 genmutaties. 
Behalve een TP53 overexpressie werd er ook een hoge Ki-67 score gevonden 
niet alleen in de primaire tumor, maar ook in het tumor recidief en de 
metastasen. In al het tumor weefsel werd dezelfde TP53 gen mutatie gevonden, 
nl Arg273Cys. Blijkbaar waren zowel de primaire tumor als het recidief en de 
metastasen afkomstig van dezelfde voorloper cel. De prognostische betekenis 
van TP53 gen mutaties zal in een grotere serie van phyllodes tumoren moeten 
worden aangetoond. 
In hoofdstuk 8 wordt besproken wat de gevolgen kUlmen zijn van de 
veranderende diagnostische en therapeutische procedures ten aanzien van het 
algemeen beleid van borstkanker. Wij concluderen daarom dat het in de 
toekomst steeds belangrijker zal worden om op histologisch maar ook op 
cytologisch materiaal met behulp van immunologische technieken celbiologische 
parameters te bepalen. 
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